U.S. patent application number 10/766079 was filed with the patent office on 2004-12-02 for pyrimidine derivatives useful as inhibitors of pkc-theta.
This patent application is currently assigned to Boehringer Ingelheim Pharmaceuticals, Inc.. Invention is credited to Cardozo, Mario G., Cogan, Derek, Cywin, Charles Lawrence, Dahmann, Georg, DiSalvo, Darren, Ginn, John David, Prokopowicz, Anthony S. III, Spero, Denice M., Young, Erick.
Application Number | 20040242613 10/766079 |
Document ID | / |
Family ID | 32825361 |
Filed Date | 2004-12-02 |
United States Patent
Application |
20040242613 |
Kind Code |
A1 |
Cardozo, Mario G. ; et
al. |
December 2, 2004 |
Pyrimidine derivatives useful as inhibitors of PKC-theta
Abstract
Disclosed are novel compounds of formula (I): 1 wherein R.sub.1,
R.sub.2 and R.sub.3 are as defined herein, which are useful as
inhibitors of PKC-theta and are thus useful for treating a variety
of diseases and disorders that are mediated or sustained through
the activity of PKC-theta, including immunological disorders and
type II diabetes. This invention also relates to pharmaceutical
compositions comprising these compounds, methods of using these
compounds in the treatment of various diseases and disorders,
processes for preparing these compounds and intermediates useful in
these processes.
Inventors: |
Cardozo, Mario G.; (San
Francisco, CA) ; Cogan, Derek; (Sandy Hook, CT)
; Cywin, Charles Lawrence; (Bethel, CT) ; Dahmann,
Georg; (Attenweiler, DE) ; DiSalvo, Darren;
(New Milford, CT) ; Ginn, John David; (New
Milford, CT) ; Prokopowicz, Anthony S. III;
(Stormville, NY) ; Spero, Denice M.; (West
Redding, CT) ; Young, Erick; (Danbury, CT) |
Correspondence
Address: |
BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P O BOX 368
RIDGEFIELD
CT
06877
US
|
Assignee: |
Boehringer Ingelheim
Pharmaceuticals, Inc.
Ridgefield
CT
Boehringer Ingelheim Pharma GmbH & Co. KG
Ingelheim
|
Family ID: |
32825361 |
Appl. No.: |
10/766079 |
Filed: |
January 27, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60443700 |
Jan 30, 2003 |
|
|
|
Current U.S.
Class: |
514/275 ;
544/329; 544/330 |
Current CPC
Class: |
A61P 37/00 20180101;
A61P 19/02 20180101; A61P 37/02 20180101; C07D 239/48 20130101;
A61P 37/08 20180101; A61P 29/00 20180101; C07D 401/14 20130101;
C07D 403/12 20130101; H01L 51/0089 20130101; A61P 17/06 20180101;
A61P 1/04 20180101; C07D 401/12 20130101; A61P 43/00 20180101; A61P
25/00 20180101; C07D 409/12 20130101; A61P 37/06 20180101; A61P
17/00 20180101; C07D 471/04 20130101; C07D 405/12 20130101; A61P
3/10 20180101 |
Class at
Publication: |
514/275 ;
544/329; 544/330 |
International
Class: |
A61K 031/506; A61K
031/505 |
Claims
We claim:
1. A compound of the following formula (I): 209wherein: R.sub.1 is
C.sub.1-8alkyl, C.sub.3-7cycloalkyl,
C.sub.3-7cycloalkyl-C.sub.1-8alkyl, naphthyl, quinolinyl,
aryl-C.sub.1-8alkyl, or heteroaryl-C.sub.1-8alkyl, wherein in each
of the C.sub.1-8alkyl groups a methylene group may optionally be
replaced by --NHC(O)-- or --C(O)NH--, and wherein each of the
C.sub.1-8alkyl groups is optionally substituted by an oxo group or
one or more C.sub.1-3alkyl groups wherein two alkyl substituents on
the same carbon atom of a C.sub.1-8alkyl group may optionally be
combined to form a C.sub.2-5 alkylene bridge, and wherein the aryl
group is optionally substituted on adjacent carbon atoms by a
C.sub.3-6alkylene bridge group wherein a methylene group is
optionally replaced by an oxygen, --S--, --S(O)--, --SO.sub.2-- or
--N(R.sub.6)-; or R.sub.1 has the following structure: 210wherein x
and y are independently 0, 1, 2, 3 or 4, provided that x+y is 2 to
4, z is 0, 1 or 2, and one or two CH.sub.2 groups in the ring may
optionally be replaced by --O--, --S--, --S(O)--, --SO.sub.2-- or
--N(R.sub.6); wherein each R.sub.1 group is optionally substituted
by one or more of the following groups: C.sub.1-6alkyl,
C.sub.3-6cycloalkyl, halogen, nitro, hydroxy, C.sub.1-6alkyloxy,
C.sub.1-6alkylthio, aryl, arylC.sub.1-6alkyl, aryloxy, arylthio,
aminosulfonyl, or amino optionally substituted by one or two
C.sub.1-6alkyl groups, wherein each aryl group is optionally
substituted by one or more C.sub.1-6alkyl, halogen, nitro, hydroxy
or amino optionally substituted by one or two C.sub.1-6alkyl
groups, and wherein in each of the C.sub.1-6alkyl groups a
methylene group may optionally be replaced by --NHC(O)-- or
--C(O)NH--, and wherein each of the C.sub.1-6alkyl groups is
optionally substituted by one or more halogens; R.sub.2 is selected
from the following groups: 211wherein: n is an integer from 3 to 8;
p is an integer from 1 to 3; q is an integer from 0 to 3; R.sub.4
and R.sub.5 are each independently selected from hydrogen,
C.sub.1-6alkyl, arylC.sub.1-6alkyl, or amidino, wherein each aryl
group is optionally substituted by one or more C.sub.1-6alkyl,
halogen, nitro, hydroxy or amino optionally substituted by one or
two C.sub.1-6alkyl groups, and wherein each of the C.sub.1-6alkyl
groups is optionally substituted by one or more halogens, and
wherein the amidino is optionally substituted by one to three
C.sub.1-6alkyl; R.sub.6 is hydrogen or C .sub.16alkyl; wherein each
R.sub.2 group is optionally substituted by one or more
C.sub.1-6alkyl, C.sub.1-6alkoxy, CN, --OH, --NH.sub.2 or halogen;
R.sub.3 is halogen, cyano, nitro, C.sub.1-6alkyl,
C.sub.1-6alkyloxycarbonyl or aminocarbonyl, wherein each of the
C.sub.1-6alkyl groups is optionally substituted by one or more
halogens; or a tautomer, pharmaceutically acceptable salt, solvate,
or amino-protected derivative thereof, with the proviso that the
specific compounds of U.S. patent application Publication No.
2003/0171359 A1 are excluded.
2. A compound of formula (I) according to claim 1, wherein: R.sub.1
is aryl-C.sub.1-4alkyl or heteroaryl-C.sub.1-4alkyl, wherein in
each of the C.sub.1-4alkyl groups a methylene group may optionally
be replaced by --NHC(O)-- or --C(O)NH--, and wherein each of the
C.sub.1-4alkyl groups is optionally substituted by an oxo group or
one or more C.sub.1-3alkyl groups wherein two alkyl substituents on
the same carbon atom of a C.sub.1-4alkyl group may optionally be
combined to form a C.sub.2-5 alkylene bridge, and wherein the aryl
group is optionally substituted on adjacent carbon atoms by a
C.sub.3-6alkylene bridge group wherein a methylene group is
optionally replaced by an oxygen, sulfur or --N(R.sub.6)-; or
R.sub.1 has the following structure: 212wherein x and y are
independently 0, 1, 2 or 3, provided that x+y is 2 to 3, and z is 0
or 1; wherein "heteroaryl" is defined as pyridyl, furyl, thienyl,
pyrrolyl, imidazolyl, or indolyl; wherein each R.sub.1 group is
optionally substituted by one or more of the following groups:
C.sub.1-6alkyl, Cl, Br, F, nitro, hydroxy, CF.sub.3, --OCF.sub.3,
--OCF.sub.2H, --SCF.sub.3, C.sub.1-4alkyloxy, C.sub.1-4alkylthio,
phenyl, benzyl, phenyloxy, phenylthio, aminosulfonyl, or amino
optionally substituted by one or two C.sub.1-3alkyl groups; R.sub.2
is selected from the following groups: 213wherein: n is an integer
from 5 to 7; p is an integer from 1 to 2; q is an integer from 1 to
2; R.sub.4 and R.sub.5 are each independently selected from
hydrogen, C.sub.1-6alkyl, arylC.sub.1-6alkyl, or amidino; R.sub.6
is hydrogen; R.sub.3 is Br, Cl, F, cyano or nitro; or a tautomer,
pharmaceutically acceptable salt, solvate, or amino-protected
derivative thereof;
3. A compound of formula (I) according to claim 1, wherein: R.sub.1
is phenyl-C.sub.1-4alkyl or naphthylC.sub.1-2alkyl, wherein each
R.sub.1 group is optionally substituted by one or more of the
following groups: methyl, Cl, Br, F, nitro, hydroxy, CF.sub.3,
--OCF.sub.3, --SCF.sub.3, C.sub.1-4alkyloxy or C.sub.1-4alkylthio;
R.sub.2 is selected from the following groups: 214wherein: R.sub.4
and R.sub.5 are each independently selected from hydrogen,
C.sub.1-3 alkyl, or amidino; R.sub.3 is Br, Cl, cyano or nitro; or
a tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof;
4. A compound of formula (I) according to claim 1, wherein: R.sub.1
is phenylCH.sub.2--wherein the phenyl group is optionally
substituted by one or more of the following groups: methyl, Cl, Br,
F, nitro, hydroxy, CF.sub.3, --OCF.sub.3, --SCF.sub.3,
C.sub.1-4alkyloxy or C.sub.1-4alkylthio; R.sub.2 is selected from
the following groups: 215R.sub.3 is nitro; R.sub.4 and R.sub.5 are
each independently selected from hydrogen, methyl, or amidino; or a
tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof.
5. A compound according to claim 1 selected from: ethyl
4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-2-[(2-chlorobenzyl)amino]pyr-
imidine-5-carboxylate;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-
-N.sup.2-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[(2S)-1,2,3,4-
-tetrahydronaphthalen-2-yl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-5-nitro-N.sup.2-[(1R)-1,2,3,4-tetrahydronaphthalen-2--
yl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-n-
itro-N.sup.2-[(1S)-1,2,3,4-tetrahydronaphthalen-2-yl]pyrimidine-2,4-diamin-
e;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(4-chlorophenyl)-
ethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-[2-(2-methylphenyl)ethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(3-methylphenyl)et-
hyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-[2-(4-methylphenyl)ethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2-fluorophenyl)et-
hyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-[2-(3-fluorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(4-fluorophenyl)et-
hyl]-5-nitropyrimidine-2,4-diamine;
N.sup.2-(2-aminobenzyl)-N.sup.4-{[4-(a-
minomethyl)cyclohexyl]methyl}-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3,5-dimethoxybenzyl)-
-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl-
}-N.sup.2-[3,5-bis(trifluoromethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
{3-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4-yl}amino)methyl]phenyl-
}methane amine;
2-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitrop-
yrimidin-2-yl]amino}methyl)phenol;
N.sup.2-(5-amino-2-chlorobenzyl)-N.sup.-
4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitropyrimidine-2,4-diamine;
4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-2-[(2-chlorobenzyl)amino]pyr-
imidine-5-carboxamide;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-
-(2-chlorobenzyl)-5-fluoropyrimidine-2,4-diamine;
3-({[4-({[4-(aminomethyl-
)cyclohexyl]methyl}amino)-5-nitropyrimidin-2-yl]amino}methyl)-N-[2-(2-meth-
lphenyl)ethyl]benzamide;
(1S,2R)-2-({[4-({[4-(aminomethyl)cyclohexyl]methy-
l}amino)-5-nitropyrimidin-2-yl]amino}methyl)cyclohexanol;
(1R,2R)-2-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidi-
n-2-yl]amino}methyl)cyclohexanol; methyl
4-({[4-(aminomethyl)cyclohexyl]me-
thyl}amino)-2-[(2-chlorobenzyl)amino]pyrimidine-5-carboxylate;
4-{[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidin-2-yl]am-
ino}-N-[2-(2-methlphenyl)ethyl]butanamide;
5-{[4-({[4-(aminomethyl)cyclohe-
xyl]methyl}amino)-5-nitropyrimidin-2-yl]amino}-N-[2-(2-methlphenyl)ethyl]p-
entanamide;
6-{[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimi-
din-2-yl]amino}-N-[2-(2-methylphenly)ethyl]hexanamide;
(1R,3R)-3-({[4-({[4-(aminomethyl)
cyclohexyl]methyl}amino)-5-nitropyrimid-
in-2-yl]amino}methyl)-4,4-dimethylcyclohexanol;
N.sup.4-({4-cis-[(dimethyl-
amino)methyl]cyclohexyl}methyl)-N.sup.2-(
1-naphthylmethyl)-5-nitropyrimid- ine-2,4-diamine;
N.sup.2-[2-(methylthio)benzyl]-5-nitro-N.sup.4-(piperidin-
-4-ylmethyl)pyrimidine-2,4-diamine;
5-nitro-N.sup.4-(piperidin-4-ylmethyl)-
-N.sup.2-{2-[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.2-(1-naphthylmethyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyrimidi-
ne-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.su-
p.2-[2-(methylthio)benzyl]-5-nitropyrimidine -2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitro-N.sup.2-{2--
[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthyl-
methyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methyl]b-
enzyl}-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methyl]benzyl}-5-nitro-N.sup.2-{2-[(trifluorom-
ethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methy-
l]benzyl}-N.sup.2-(1-naphthylmethyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-N.sup.2-[2-(methylthio)benzyl]-5-
-nitropyrimidine-2,4-diamine;
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-n-
itro-N.sup.2-{2-[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-N.sup.2-(1-naphthylmethyl)-5-nit-
ropyrimidine-2,4-diamine;
N.sup.2-(2-chlorobenzyl)-N.sup.4-[(1-methylpiper-
idin-4-yl)methyl]-5-nitropyrimidine-2,4-diamine;
N.sup.2-(2-methoxybenzyl)-
-N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-methoxybenzyl)-5-n-
itropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5--
nitro-N.sup.2-[2-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methly}-N.sup.2-(2,4-dichlorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(3-methoxybenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[4-fluoro-2-(trifluor-
omethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(3-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(pyridin-2-yl-
methyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(3-chlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-chlorobenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-(4-bromobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,4-dimethoxybenzyl)-
-5-nitropyrimidine-2,4diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-[2-chloro-5-(trifluoromethyl)benzyl]-5-nitropyrimide-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,5-dichlorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-5-nitro-N.sup.2-[2-(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-6-methylbenzyl)-5-
-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}--
N.sup.2-(2,3-dichlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-furylmethyl)-5-nit-
ropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nit-
ro-N.sup.2-(thien-2-ylmethyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chlorobenzyl)-5-me-
thylpyrimidine-2,4-diamine;
N.sup.4-(6-aminohexyl)-N.sup.2-(2-chlorobenzyl-
)-5-nitropyrimidine-2,4-diamine;
N.sup.4-[4-(aminomethyl)benzyl]-N.sup.2-(-
2-chlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-(7-aminoheptyl)-N.s-
up.2-(2-chlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[3-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chlorobenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-(1-methyl-1-phenylethyl)-5-nitropyrimidine-2,4-diamine;
4-(4,4'-bipiperidin-1-yl)-N-(2-chlorobenzyl)-5-nitropyrimidin-2-amine;
N.sup.2-(2-chlorobenzyl)-N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}me-
thyl)-5-nitropyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(2,5-difluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[4-(difluoromethoxy)b-
enzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-(2-ethoxybenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[(1S)-1-pheny-
lethyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(2-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-fluorobenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-(3-chloro-2-fluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(4-pentylbenz-
yl)pyrimidine-2,4-diamine
4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-
-butoxybenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-N.sup.2-(2,3-dimethoxybenzyl)-5-nitropyrimidine-2,4-diamin-
e
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,5-dimethoxybenzyl-
)-5-nitropyrimidine-2,4-diamine;
N.sup.2-(2-chlorobenzyl)-N.sup.4-[7-(dime-
thylamino)heptyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)- cyclohexyl]methyl}-N.sup.2-(1,1
'-biphenyl-2-ylmethyl)-5-nitropyrimidine -2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-fluo-
robenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(2,4-difluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-fluoro-4-methylben-
zyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(2,3-difluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-(2-chlorobenz-
yl)pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.su-
p.2-(2,6-dimethoxybenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,6-difluorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-[2-fluoro-3-(trifluoromethyl)benzyl]-5-nitropyrimidine-2,4-diamin-
e;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-chloro-2-fluorob-
enzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-5-nitro-N.sup.2-(1-phenylcyclopropyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[1-(2-chlorophenyl)-1-
-methylethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-(2,3-dihydro-1-benzofuran-5-ylmethyl)-5-nitropyrimi-
dine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[(1,-
5-dimethyl-1H-pyrrol-2-yl)methyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-bromobenzyl)-5-nit-
ropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.su-
p.2-(2,3-dimethylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,4-dimethylbenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(2,5-dimethylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-fluoro-5-(trifluor-
omethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diam-
ine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-{2-[(trif-
luoromethyl)thio]benzyl}primidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(3-fluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(6-chloro-2-fluoro-3--
methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-(2-chloro-6-fluoro-3-methylbenzyl)-5-nitropyrimidin-
e-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-2-napht-
hyl-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]met-
hyl}-N.sup.2-(1-naphthylmethyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-fluoro-4-(trifluor-
omethyl)benzyl]-5-nitropryimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(4-chloro-2-methylbenzyl)-5-nitropyrimidine-2,4-d-
iamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(5-chloro-2-me-
thylbenzyl)-5-nitropyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-N.sup.2-(3-chloro-2-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[5-fluoro-2-(trifluor-
omethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(5-chloro-2-fluorobenzyl)-5-nitropyrimidine-2,4-d-
iamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-difluoro--
4-methylbenzyl)-5-nitropyrimide-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-(5-fluoro-2-methylbenzyl)-5-nitropyrimidine-2,4-dia-
mine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-1-naphthyl-5-nit-
ropyrimidine-2,4-diamine;
{4-trans-[({2-[(2-chlorobenzyl)amino]-5-nitropyr-
imidin-4-yl}amino)methyl]cyclohexyl}methanol;
N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-5-bromo-N.sup.2-(2,5-dichlorobenzyl)pyrimidine-2,4-diamine-
;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-(2,4-dichlor-
obenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl-
}-5-bromo-N.sup.2-(2-bromobenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(cyclohexylmethyl)-5--
nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N-
.sup.2-(2-naphthylmethyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-nm-[2-(trifluorometho-
xy)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]meth-
yl}-5-bromo-N.sup.2-[2-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(difluoromethoxy)b-
enzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-[3-(difluoromethoxy)benzyl]-5-nitropyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-4-fluoro
benzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-N.sup.2-(2-chloro-3,6-difluorobenzyl)-5-nitropyrimidine
-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-
-(2,3,5-trifluorobenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)c-
yclohexyl]methyl}-5-nitro-N.sup.2-(2,3,4,5-tetrafluorobenzyl)pyrimidine-2,-
4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[(1-
R)-1-phenylethyl]pyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]met- hyl}-N.sup.2-2,3-dihydro- 1
H-inden-2-yl-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[(1S)-2,3-dihydro-1H--
inden-1-yl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cycloh-
exyl]methyl}-N.sup.2-[(1R)-2,3-dihydro-1H-inden-1-yl]-5-nitropyrimidine-2,-
4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-chloro-1-
-naphthyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohe-
xyl]methyl}-N.sup.2-(4-methoxy-2-naphthyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-quinolin-6-yl-
pyrimidine-2,4-diamine;
N.sup.4-{[4-trans-(aminomethyl)cyclohexyl]methyl}--
N.sup.2-(2,5-dichlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-trans-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobe-
nzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-N.sup.2-[2-(2-chlorophenyl)ethyl]-5-nitropyrimidine
-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(3-chlorophenyl)et-
hyl]-5-nitropyrimidine -2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-N.sup.2-(2-chloro-6-phenoxybenzyl)-5-nitropyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-2-naphthylpyrimidin-
e-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-
-(1-naphthylmethyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cycloh-
exyl]methyl}-5-nitro-N.sup.2-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine;
4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-2-[(2-chlorobenzyl)amino]pyr-
imidine-5-carbonitrile;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.-
2-[4-(dimethylamino)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-trans-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-bromobenzyl)-
-5-nitropyrimidine-2,4-diamine;
N.sup.4-(7-aminoheptyl)-N.sup.2-(2-bromobe-
nzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-(7-aminoheptyl)-N.sup.2-(2,5--
dichlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N-({4-[({2-[(2-chlorobenzyl-
)amino]-5-nitropyrimidin-4-yl}amino)methyl]cyclohexyl}methyl)guanidine;
N.sup.2-(3-aminobenzyl)-N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nit-
ropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-ni-
tro-N.sup.2-(2-nitrobenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-N.sup.2-[2-(2-bromophenyl)ethyl]-5-nitropyrimidine
-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-brom-
obenzyl)-5-chloropyrimidine-2,4-diamine;
(4-{[(2-{[2-(1H-indol-3-yl)ethyl]-
amino}-5-nitropyrimidin-4-yl)amino]methyl}cyclohexyl)methanaminium
chloride;
N-({3-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4-yl}amino)-
methyl]cyclohexyl}methyl)guanidine;
3-({[4-({[4-(aminomethyl)cyclohexyl]me-
thyl}amino)-5-nitropyrimidin-2-yl]amino}methyl)phenol;
(4-{[(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-5-nitropyrimidin-4-yl)amino]me-
thyl}cyclohexyl)methanaminium chloride;
N.sup.2-(2-chlorobenzyl)-N.sup.4-(-
{4-cis-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitropyrimidine-2,4-dia-
mine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-chloro-N.sup.2-(2-chlo-
robenzyl)pyrimidine-2,4-diamine;
N.sup.2-(2-chlorobenzyl)-5-nitro-N.sup.4--
(piperidin-4-ylmethyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-5-nitro-N.sup.2-(2-phenylethyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(3-phenylprop-
yl)pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-ni-
tro-N.sup.2-(4-phenylbutyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-5-nitro-N.sup.2-(2-phenylpropyl)pyrimidine-2,4-diamin-
e;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(4-methoxyphenyl-
)ethyl]-5-nitropyrimidine -2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-N.sup.2-[2-(3-methoxyphenyl)ethyl]-5-nitropyrimidine
-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2-m-
ethoxyphenyl)ethyl]-5-nitropyrimidine -diamine;
4-[({2-[(2-chlorobenzyl)am-
ino]-5-nitropyrimidin-4-yl}amino)methyl]piperidine-1-carboximide;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3,5-dichlorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-(5-aminopentyl)-N.sup.2-(2-chlorobe-
nzyl)-5-nitropyrimidine-2,4-diamine;
2-(benzylamino)-4-(1,4,6,7-tetrahydro-
-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidine;
2-(4-chlorobenzylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-
-5-nitro-pyrimidine;
2-(2-chlorobenzylamino)-4-(1,4,6,7-tetrahydro-imidazo-
[4,5-c]pyridin-5-yl)-5-nitro-pyrimidine;
2-(benzylamino)-4-(1,4,6,7-tetrah-
ydro-imidazo[4,5-c]pyridin-5-yl)-5-nitro-pyrimidine; or a tautomer,
pharmaceutically acceptable salt, solvate, or amino-protected
derivative thereof.
6. A compound according to claim 1, selected from:
N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-5-nitro-N.sup.2-[(2R)-1,2,3,4-tetrahydronaphthalen-2--
yl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-[2-(4-chlorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(3-methylphenyl)et-
hyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-[4-{[4-(aminomethyl)cyclohexyl-
]methyl}-N.sup.2-[2-(4-methylphenyl)ethyl]-5-nitropyrimide-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(3-fluorophenyl)et-
hyl]-5-nitropyrimidine -2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-N.sup.2-[2-(4-fluorophenyl)ethyl]-5-nitropyrimidine
-2,4-diamine;
(1R,3R)-3-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidi-
n-2-yl]amino}methyl)-4,4-dimethylcyclohexanol;
N.sup.4-({4-cis-[(dimethyla-
mino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthylmethyl)-5-nitropyrimidin-
e-2,4-diamine;
N.sup.2-[2-(methylthio)benzyl]-5-nitro-N.sup.4-(piperidin-4-
-ylmethyl)pyrimidine-2,4-diamine;
5-nitro-N.sup.4-(piperidin-4-ylmethyl)-N-
.sup.2-{2-[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.2-(1-naphthylmethyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyrimidi-
ne-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.su-
p.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitro-N.sup.2-{2--
[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthyl-
methyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methyl]b-
enzyl}-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methyl]benzyl}-5-nitro-N.sup.2-{2-[(trifluorom-
ethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-[(1-methylpiperidin-4-yl-
)methyl]-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-nitro-N.sup.2-{2-[(trifluorome-
thyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(2-methoxybenzyl)-5-nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[2-(trifluoro-
methyl)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-(2,4-dichlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[4-fluoro-2-(trifluor-
omethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(3-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-chlorobenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-(4-bromobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-chloro-5-(trifluor-
omethyl)benzyl]-5-nitroprimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-N.sup.2-(2,5-dichlorobenzyl)-5-nitropyrimidine-2,4-diamine-
;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[2-(trifluor-
omethoxy)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-N.sup.2-(2-chloro-6-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[3-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(2-chlorobenzyl)-5-nitropyrimidine-2,4-diamine
N.sup.2-(2-chlorobenzyl)-N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}me-
thyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-N.sup.2-(2,5-difluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-ethoxybenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-(2-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-fluorobenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s-
up.2-(3-chloro-2-fluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(1,1'-biphenyl-2-ylme-
thyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-N.sup.2-(2,4-difluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-difluorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(2,6-difluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-fluoro-3-(trifluor-
omethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(4-chloro-2-fluorobenzyl)-5-nitropyrimidine-2,4-d-
iamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-bromobenzyl-
)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methy-
l}-N.sup.2-(2,3-dimethylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(methylthio)benzyl-
]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methy-
l}-5-nitro-N.sup.2-{2-[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine-
;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-fluorobenzyl)-5-n-
itropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.-
sup.2-(6-chloro-2-fluoro-3-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-6-fluoro-3--
methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-2-naphthyl-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(1-naphthylmethyl)-5--
nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N-
.sup.2-(4-chloro-2-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(5-chloro-2-methylben-
zyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(3-chloro-2-methylbenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[5-fluoro-2-(trifluor-
omethyl)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(5-chloro-2-fluorobenzyl)-5-nitropyrimidine-2,4-d-
iamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-difluoro--
4-methylbenzyl)-5-nitropyrimidine-2,4diamine;
N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-N.sup.2-(5-fluoro-2-methylbenzyl)-5-nitropyrimidine-2,4-di-
amine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-(2,5-di-
chlorobenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]m-
ethyl}-5-bromo-N.sup.2-(2-bromobenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(cyclohexylmethyl)-5--
nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-
-bromo-N.sup.2-[2-(trifluoromethyl)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(difluoromethoxy)b-
enzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-(2-chloro-4-fluorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-3,6-difluor-
obenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-5-nitro-N.sup.2-(2,3,5-trifluorobenzyl)pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-2,3-dihydro-1H-inden--
2-yl-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(4-chloro-1-naphthyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-methoxy-2-naphthyl-
)-5-nitropyrimidine-2,4-diamine;
4-{[4-(aminomethyl)cyclohexyl]methyl}-5-n-
itro-N.sup.2-quinolin-6-ylpyrimidine-2,4-diamine;
N.sup.4-{[4-trans-(amino-
methyl)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobenzyl)-5-nitropyrimidine-2-
,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2-chlo-
rophenyl)ethyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-[2-(3-chlorophenyl)ethyl]-5-nitropyrimidine-2,4-d-
iamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-2-naph-
thylpyrimidine-2,4-diamine;
4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-2-
-[(2-chlorobenzyl)amino]pyrimidine-5-carbonitrile;
N.sup.4-{[4-trans-(amin-
omethyl)cyclohexyl]methyl]-}N.sup.2-(2-bromobenzyl)-5-nitropyrimidine-2,4--
diamine;
N.sup.4-(7-aminoheptyl)-N.sup.2-(2-bromobenzyl)-5-nitropyrimidine-
-2,4-diamine;
N.sup.4-(7-aminoheptyl)-N.sup.2-(2,5-dichlorobenzyl)-5-nitro-
pyrimidine-2,4-diamine;
N-({4-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidi- n-4-yl}amino)
methyl]cyclohexyl}methyl)guanidine; N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-5-nitro-N.sup.2-(2-nitrobenzyl)pyrimidine-2,4-diamine
4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2-bromophenyl)ethyl]-5--
nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N-
.sup.2-(2-bromobenzyl)-5-chloropyrimidine-2,4-diamine;
N-({3-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4-yl}amino)methyl]cyc-
lohexyl}methyl)guanidine;
3-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino-
)-5-nitropyrimidin-2-yl]amino}methyl)phenol;
N.sup.2-(2-chlorobenzyl)-N.su-
p.4-({4-cis-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitropyrimidine-2,-
4-diamine;
N.sup.2-(2-chlorobenzyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)-
pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitr-
o-N.sup.2-(2-phenylethyl)pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)c-
yclohexyl]methyl}-5-nitro-N.sup.2-(4-phenylbutyl)pyrimidine-2,4-diamine
or a tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof.
7. A compound according to claim 1, selected from:
N.sup.4-({4-[(dimethyla-
mino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthylmethyl)-5-nitropyrimidin-
e-2,4-diamine;
N.sup.2-[2-(methylthio)benzyl]-5-nitro-N.sup.4-(piperidin-4-
-ylmethyl)pyrimidine-2,4-diamine;
5-nitro-N.sup.4-(piperidin-4-ylmethyl)-N-
.sup.2-{2-[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.2-(1-naphthylmethyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyrimidi-
ne-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.su-
p.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitro-N.sup.2-{2--
[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthyl-
methyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methyl]b-
enzyl}-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{4-[(dimethylamino)methyl]benzyl}-5-nitro-N.sup.2-{2-[(trifluorom-
ethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-[(1-methylpiperidin-4-yl-
)methyl]-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-nitro-N.sup.2-{2-[(trifluorome-
thyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(2-methoxybenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[2-(trifluoro-
methoxy)benzyl]pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl-
]methyl}-N.sup.2-(2,3-dichlorobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[3-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chlorobenzyl)-5-ni-
tropyrimidine-2,4-diamine;
N.sup.2-(2-chlorobenzyl)-N.sup.4-({4-[(dimethyl-
amino)methyl]cyclohexyl}methyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-bromobenzyl)-5-nit-
ropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.su-
p.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-{2-[(trifluor-
omethyl)thio]benzyl}pyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclo-
hexyl]methyl}-N.sup.2-(1-naphthylmethyl)-5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobenzyl)--
5-nitropyrimidine-2,4-diamine;
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-
-N.sup.2-(2-bromobenzyl)-5-nitropyrimidine-2,4-diamine;
N.sup.2-(2-chlorobenzyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyrimidine-
-2,4-diamine; or a tautomer, pharmaceutically acceptable salt,
solvate, or amino-protected derivative thereof.
8. A pharmaceutical composition comprising a compound according to
claim 1, and at least one pharmaceutically acceptable carrier or
adjuvant.
9. A method of treating a disease or disorder that is mediated or
sustained through the activity of PKC-theta in a patient comprising
administering to said patient a therapeutically effective amount of
a compound according to claim 1.
10. A method of treating a disease or disorder associated with the
activation of T cells in a patient comprising administering to said
patient a therapeutically effective amount of a compound according
to claim 1.
11. A method of treating an immunological disorder in a patient
comprising administering to said patient a therapeutically
effective amount of a compound according to claim 1.
12. A method of treating an inflammatory disease, an autoimmune
disease, organ and bone marrow transplant rejection, acute or
chronic inflammation, allergies, contact dermatitis, psoriasis,
rheumatoid arthritis, multiple sclerosis, type I diabetes,
inflammatory bowel disease, Guillain-Barre syndrome, Crohn's
disease, ulcerative colitis, graft versus host disease or lupus
erythematosus in a patient comprising administering to said patient
a therapeutically effective amount of a compound according to claim
1.
13. A method of treating type II diabetes in a patient comprising
administering to said patient a therapeutically effective amount of
a compound according to claim 1.
14. A method of making a compound of the formula (I) below:
216wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in claim 1,
said method comprising: (a) reacting the compound of formula (II),
wherein X and X' are halogens, with an amine R'R"NH, wherein
R.sub.2=--NR'R", in the presence of a base to form a compound of
formula (III): 217(b) reacting the compound of formula (III) with
an amine R.sub.1NH.sub.2 to form the compound of formula (I):
218
15. A method of making a compound of the formula (I) below:
219wherein R.sub.1 and R.sub.2 are as defined in claim 1 and
R.sub.3 is NO.sub.2, said method comprising: (a) reacting the
compound of formula (II), wherein X and X' are halogens, with a
thiocyanate salt to produce a compound of formula (VI): 220(b)
reacting the compound of formula (VI) with R.sub.1NH.sub.2 in the
presence of a base to provide the compound of formula (VII): 221(c)
reacting the compound of formula (VII) with an amine R'R"NH,
wherein R.sub.2=--NR'R", to provide the compound of formula (I):
222
Description
RELATED APPLICATIONS
[0001] This application claims benefit to U.S. Provisional
Application No. 60/443,700, filed Jan. 30, 2003, and said
application is herein incorporated by reference in its
entirety.
FIELD OF THE INVENTION
[0002] This invention relates to substituted pyrimidine derivatives
which are useful as inhibitors of PKC-theta and are thus useful for
treating a variety of diseases and disorders that are mediated or
sustained through the activity of PKC-theta, including
immunological disorders and type II diabetes. This invention also
relates to pharmaceutical compositions comprising these compounds,
methods of using these compounds in the treatment of various
diseases and disorders, processes for preparing these compounds and
intermediates useful in these processes.
BACKGROUND OF THE INVENTION
[0003] The protein kinase C family is a group of serine/threonine
kinases that is comprised of twelve related isoenzymes. These
kinases are expressed in a wide range of tissues and cell types.
Its members are encoded by different genes and are sub-classified
according to their requirements for activation. The classical PKC
enzymes (cPKC) require diacylglycerol (DAG), phosphatidylserine
(PS) and calcium for activation. The novel PKC's (nPKC) require DAG
and PS but are calcium independent. The atypical PKC's (aPKC) do
not require calcium or DAG.
[0004] PKC-theta is a member of the nPKC sub-family. It has a
restricted expression pattern, found predominantly in T cells and
skeletal muscle. Upon T cell activation, a supramolecular
activation complex (SMAC) forms at the site of contact between the
T cell and antigen presenting cell (APC). PKC-theta is the only PKC
isoform found to localize at the SMAC (C. Monks et al., Nature,
1997, 385, 83), placing it in proximity with other signaling
enzymes that mediate T cell activation processes. In another study
(G. Baier-Bitterlich et al., Mol. Cell. Biol., 1996, 16, 842) the
role of PKC-theta in the activation of AP-1, a transcription factor
important in the activation of the IL-2 gene, was confirmed. In
unstimulated T cells, constitutively active PKC-theta stimulated
AP-1 activity while in cells with dominant negative PKC-theta, AP-1
activity was not induced upon activation by PMA. Other studies
showed that PKC-theta, via activation of I.kappa.B kinase beta,
mediates activation of NF-.kappa.B induced by T cell receptor/CD28
co-stimulation (N. Coudronniere et al., Proc. Nat. Acad. Sci.
U.S.A., 2000, 97, 3394; X. Lin et al., Moll. Cell. Biol., 2000, 20,
2933). Proliferation of peripheral T cells from PKC-theta knockout
mice, in response to T cell receptor (TCR)/CD28 stimulation was
greatly diminished compared to T cells from wild type mice. In
addition, the amount of IL-2 released from the T cells was also
greatly reduced (Z. Sun et al., Nature, 2000, 404, 402). Otherwise,
the PKC-theta knockout mice seemed normal and were fertile.
[0005] The studies cited above and other studies confirm the
critical role of PKC-theta in T cell activation and subsequent
release of cytokines such as IL-2 and T cell proliferation (A.
Altman et al., Immunology Today, 2000, 21, 567). Thus an inhibitor
of PKC-theta would be of therapeutic benefit in treating
immunological disorders and other diseases mediated by the
inappropriate activation of T cells.
[0006] It has been well established that T cells play an important
role in regulating the immune response (Powrie and Coffman,
Immunology Today, 1993, 14, 270). Indeed, activation of T cells is
often the initiating event in immunological disorders. Following
activation of the TCR, there is an influx of calcium that is
required for T cell activation. Upon activation, T cells produce
cytokines, including as IL-2, leading to T cell proliferation,
differentiation, and effector function. Clinical studies with
inhibitors of IL-2 have shown that interference with T cell
activation and proliferation effectively suppresses immune response
in vivo (Waldmann, Immunology Today, 1993, 14, 264). Accordingly,
agents that inhibit T lymphocyte activation and subsequent cytokine
production are therapeutically useful for selectively suppressing
the immune response in a patient in need of such immunosuppression
and therefore are useful in treating immunological disorders such
as autoimmune and inflammatory diseases.
[0007] In addition, PKC theta activation has been shown to be
associated with insulin resistance in skeletal muscle (M. E.
Griffen et al., Diabetes, 1999, 48, 1270). Therefore inhibitors of
PKC-theta may also be useful for treating type II diabetes.
[0008] Dahmann et al, U.S. application Ser. No. 10/271,763, filed
Oct. 16, 2002, (now U.S. patent application Publication No.
2003/0171359 A1) discloses pyrimidine derivatives as inhibitors of
various protein kinases such as SRC kinase, PLK kinase and
particularly cyclin-dependent kinases (CDKs) and Aurora B. WO
00/75113 and U.S. Pat. No. 6,432,963 describe pyrimidine
carboxamides as inhibitors of Syk tyrosine kinase. WO 01/00213
discloses heteroaryl substituted pyrimidines as SRC kinase
inhibitors. WO 97/19065 describes substituted 2-anilinopyrimidine
compounds as inhibitors of certain protein kinases. WO 02/096887
and WO 02/096888 both disclose 2-anilinopyrimidine derivatives as
inhibitors of cyclin-dependent kinases. WO 03/106451 discloses
certain substituted diaminopyrimidine compounds as inhibitors of
PKC-theta.
[0009] There is a continuing need in the art for compounds that are
potent and selective inhibitors of PKC-theta.
BRIEF SUMMARY OF THE INVENTION
[0010] In a general aspect, the present invention is directed to
the compounds of the following formula (I): 2
[0011] wherein R.sub.1, R.sub.2 and R.sub.3 are as defined herein,
as well as the tautomers, pharmaceutically acceptable salts,
solvates, and amino-protected derivatives thereof. It has been
found that the compounds of formula (I) have valuable
pharmacological properties, particularly an inhibiting activity on
PKC-theta. Many of the compounds of the invention are not only
potent inhibitors of PKC-theta but are also selective for the
inhibition of PKC-theta as compared to one or more other protein
kinases.
[0012] In another aspect, the present invention is directed to a
method of inhibiting PKC-theta activity in a patient comprising
administering to the patient a compound of the present invention as
described above.
[0013] In another aspect, the present invention is directed to a
method of treating a disease or disorder associated with the
activation of T cells comprising administering to a patient in need
of such treatment a compound of the present invention as described
above.
[0014] In another aspect, the present invention is directed to a
method of treating an immunological disorder comprising
administering to a patient in need of such treatment a compound of
the present invention as described above. Examples of such
immunological disorders that may be treated include, for example,
inflammatory diseases, autoimmune diseases, organ and bone marrow
transplant rejection and other disorders associated with T cell
mediated immune response, including acute or chronic inflammation,
allergies, contact dermatitis, psoriasis, rheumatoid arthritis,
multiple sclerosis, type I diabetes, inflammatory bowel disease,
Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, graft
versus host disease (and other forms of organ or bone marrow
transplant rejection) and lupus erythematosus.
[0015] In another aspect, the present invention is directed to a
method of treating type II diabetes comprising administering to a
patient in need of such treatment a compound of the present
invention as described above.
[0016] In yet additional aspects, the present invention is directed
to pharmaceutical compositions comprising the above-mentioned
compounds, processes for preparing the above-mentioned compounds
and intermediates used in these processes.
DETAILED DESCRIPTION OF THE INVENTION
Definition of Terms and Conventions Used
[0017] Terms not specifically defined herein should be given the
meanings that would be given to them by one of skill in the art in
light of the disclosure and the context. As used in the present
specification and claims, however, unless specified to the
contrary, the following terms have the meaning indicated and the
following conventions are adhered to.
[0018] A. Chemical Nomenclature, Terms, and Conventions
[0019] In general, for groups comprising two or more subgroups, the
last named group is the radical attachment point, for example,
"alkylaryl" means a monovalent radical of the formula Alk-Ar-,
while "arylalkyl" means a monovalent radical of the formula Ar-Alk-
(where Alk is an alkyl group and Ar is an aryl group). Furthermore,
the use of a term designating a monovalent radical where a divalent
radical is appropriate shall be construed to designate the
respective divalent radical and vice versa. Unless otherwise
specified, conventional definitions of terms control and
conventional stable atom valences are presumed and achieved in all
formulas and groups.
[0020] All alkyl groups shall be understood as being branched or
unbranched unless otherwise specified. Other more specific
definitions are as follows:
[0021] The term "halogen" as used in the present specification
shall be understood to mean bromine, chlorine, fluorine or
iodine.
[0022] The term "heteroaryl" refers to a stable 5 or 6 membered,
monocyclic aromatic heterocycle radical, wherein the heterocycle
radical is optionally fused to either an aryl, e.g. benzene, or to
a second 5 or 6 membered, monocyclic aromatic heterocycle to form
in each case a bicyclic heteroaryl group. Each heterocycle consists
of carbon atoms and from 1 to 3 heteroatoms chosen from nitrogen,
oxygen and sulfur. The heterocycle may be attached by any atom of
the cycle, which results in the creation of a stable structure.
Example "heteroaryl" radicals include, pyridyl, pyrimidinyl,
pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl,
furyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl,
thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl,
benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl,
benzothiofuranyl, benzothiazolyl, quinazolinyl and indazolyl.
[0023] The term "aryl" shall be understood to mean a 6-10 membered
monocyclic or bicyclic aromatic carbocycle, and includes, for
example, phenyl and naphthyl; other terms comprising "aryl" will
have the same definition for the aryl component, and examples of
these moieties include: arylalkyl, aryloxy or arylthio.
[0024] The term "oxo" refers to a double-bonded oxygen group
(.dbd.O).
[0025] The phrases "wherein each of the C.sub.1-6alkyl groups",
"wherein each of the C.sub.1-8alkyl groups" or "wherein each of the
aryl groups" or similar language in a definition is intended to
refer to the indicated groups when either alone or as part of
another chemical group if such combined groups are provided for in
a definition. For example, the language "wherein each of the
C.sub.1-6alkyl groups" refers to C.sub.1-6alkyl groups as well as
C.sub.1-6alkyl groups when attached to other groups, e.g., the
C.sub.1-6alkyl portion of a C.sub.1-6alkyloxy or
aryl-C.sub.1-6alkyl group, if such groups are provided for in a
definition.
[0026] The term "amino protected derivatives" shall be understood
to mean compounds of formula (I) wherein one or more of the amine
groups are protected by suitable amino protecting groups. Amino
protecting groups that may be used include, for example,
alkoxycarbonyl groups, such as tert-butyloxycarbonyl (Boc) and
ethoxycarbonyl, Mannich bases, Schiff bases and amino acids. As
would be understood by a person skilled in the art, such amino
protected compounds may be useful as intermediates in the
preparation of other compounds of formula (I), e.g., as described
in the synthetic processes below, and/or may themselves be useful
as prodrugs that can be administered to a patient to be converted
in vivo into a PKC-theta inhibitor having the resulting
pharmacologic and therapeutic effects expected from the inhibition
of PKC-theta in a patient.
[0027] The term "pharmaceutically acceptable salts" include those
derived from pharmaceutically acceptable inorganic and organic
acids and bases. Examples of suitable acids include hydrochloric,
hydrobromic, carbonic, sulfuric, nitric, perchloric, fumaric,
maleic, phosphoric, glycolic, lactic, salicylic, succinic,
toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic,
formic, benzoic, malonic, naphthalene-2-sulfonic and
benzenesulfonic acids. Other acids, such as oxalic acid, while not
themselves pharmaceutically acceptable, may be employed in the
preparation of salts useful as intermediates in obtaining the
compounds of this invention and their pharmaceutically acceptable
acid addition salts. Salts derived from appropriate bases include
alkali metal (e.g., sodium), alkaline earth metal (e.g.,
magnesium), ammonium and N-(C.sub.1-4 alkyl).sub.4.sup.+ salts.
[0028] The term "solvate" means a physical association of a
compound with one or more solvent molecules or a complex of
variable stoichiometry formed by a solute (for example, a compound
of Formula (I)) and a solvent, for example, water, ethanol, or
acetic acid. This physical association may involve varying degrees
of ionic and covalent bonding, including hydrogen bonding. In
certain instances, the solvate will be capable of isolation, for
example, when one or more solvent molecules are incorporated in the
crystal lattice of the crystalline solid. In general, the solvents
selected do not interfere with the biological activity of the
solute. Solvates encompasses both solution-phase and isolatable
solvates. Representative solvates include hydrates, ethanolates,
methanolates, and the like.
[0029] The term "hydrate" means a solvate wherein the solvent
molecule(s) is/are H.sub.2O.
[0030] The term "compounds of the invention" and equivalent
expressions are meant to embrace compounds of Formula (I) as herein
described, including the tautomers, pharmaceutically acceptable
salts, solvates, and amino-protected derivatives thereof, where the
context so permits. In general, the compounds of the invention and
the formulas designating the compounds of the invention are
understood to only include the stable compounds thereof and exclude
unstable compounds, even if an unstable compound might be
considered to be literally embraced by the compound formula.
[0031] The term "stable compound" means a compound that is
sufficiently robust to survive isolation to a useful degree of
purity from a reaction mixture, and formulation into an efficacious
therapeutic agent. For example, a compound which would have a
"dangling valency" is not a compound contemplated by the
invention.
[0032] Specific compounds of the present invention may be
identified in the present specification by chemical name and/or
chemical structure. In the event of any conflict between the
chemical name and chemical structure, the chemical structure will
control.
[0033] B. Isomer Terms and Conventions
[0034] In general, all tautomeric and isomeric forms and mixtures
thereof, for example, individual geometric isomers, stereoisomers,
enantiomers, diastereomers, racemates, racemic or non-racemic
mixtures of stereoisomers, mixtures of diastereomers, or mixtures
of any of the foregoing forms of a chemical structure or compound
is intended, unless the specific stereochemistry or isomeric form
is specifically indicated in the compound name or structure.
[0035] It is well-known in the art that the biological and
pharmacological activity of a compound is sensitive to the
stereochemistry of the compound. Thus, for example, enantiomers
often exhibit strikingly different biological activity including
differences in pharmacokinetic properties, including metabolism,
protein binding, and the like, and pharmacological properties,
including the type of activity displayed, the degree of activity,
toxicity, and the like. Thus, one skilled in the art will
appreciate that one enantiomer may be more active or may exhibit
beneficial effects when enriched relative to the other enantiomer
or when separated from the other enantiomer. Additionally, one
skilled in the art would know how to separate, enrich, or
selectively prepare the enantiomers of the compounds of the present
invention from this disclosure and the knowledge in the art.
[0036] Preparation of pure stereoisomers, e.g. enantiomers and
diastereomers, or mixtures of desired enantiomeric excess (ee) or
enantiomeric purity, are accomplished by one or more of the many
methods of (a) separation or resolution of enantiomers, or (b)
enantioselective synthesis known to those of skill in the art, or a
combination thereof. These resolution methods generally rely on
chiral recognition and include, for example, chromatography using
chiral stationary phases, enantioselective host-guest complexation,
resolution or synthesis using chiral auxiliaries, enantioselective
synthesis, enzymatic and nonenzymatic kinetic resolution, or
spontaneous enantioselective crystallization. Such methods are
disclosed generally in Chiral Separation Techniques: A Practical
Approach (2nd Ed.), G. Subramanian (ed.), Wiley-VCH, 2000; T. E.
Beesley and R. P. W. Scott, Chiral Chromatography, John Wiley &
Sons, 1999; and Satinder Ahuja, Chiral Separations by
Chromatography, Am. Chem. Soc., 2000. Furthermore, there are
equally well-known methods for the quantitation of enantiomeric
excess or purity, for example, GC, HPLC, CE, or NMR, and assignment
of absolute configuration and conformation, for example, CD ORD,
X-ray crystallography, or NMR.
[0037] C. Pharmaceutical Administration Terms and Conventions
[0038] The term "patient" includes both human and non-human
mammals.
[0039] The term "therapeutically effective amount" means an amount
of a compound according to the invention which, when administered
to a patient in need thereof, is sufficient to effect treatment for
disease-states, conditions, or disorders for which the compounds
have utility. Such an amount would be sufficient to elicit the
biological or medical response of a tissue, system, or patient that
is sought by a researcher or clinician. The amount of a compound of
according to the invention which constitutes a therapeutically
effective amount will vary depending on such factors as the
compound and its biological activity, the composition used for
administration, the time of administration, the route of
administration, the rate of excretion of the compound, the duration
of treatment, the type of disease-state or disorder being treated
and its severity, drugs used in combination with or coincidentally
with the compounds of the invention, and the age, body weight,
general health, sex, and diet of the patient. Such a
therapeutically effective amount can be determined routinely by one
of ordinary skill in the art having regard to their own knowledge,
the state of the art, and this disclosure.
[0040] The phrase "disease or disorder associated with the
activation of T cells" and similar expressions mean that the
activation of T cells is a contributing factor to either the origin
or continuation of the disease or disorder in the patient.
Embodiments of the Invention
[0041] In its broadest generic aspect, the invention provides novel
compounds of the formula (I) below: 3
[0042] wherein:
[0043] R.sub.1 is C.sub.1-8alkyl, C.sub.3-7cycloalkyl,
C.sub.3-7cycloalkyl-C.sub.1-8alkyl, naphthyl, quinolinyl,
aryl-C.sub.1-8alkyl, or heteroaryl-C.sub.1-8alkyl, wherein in each
of the C.sub.1-8alkyl groups a methylene group may optionally be
replaced by --NHC(O)-- or --C(O)NH--, and wherein each of the
C.sub.1-8alkyl groups is optionally substituted by an oxo group or
one or more C.sub.1-3alkyl groups wherein two alkyl substituents on
the same carbon atom of a C.sub.1-8alkyl group may optionally be
combined to form a C.sub.2-5 alkylene bridge, and wherein the aryl
group is optionally substituted on adjacent carbon atoms by a
C.sub.3-6alkylene bridge group wherein a methylene group is
optionally replaced by an oxygen, --S--, --S(O)--, --SO.sub.2-- or
--N(R.sub.6)--;
[0044] or R.sub.1 has the following structure: 4
[0045] wherein x and y are independently 0, 1, 2, 3 or 4, provided
that x+y is 2 to 4, z is 0, 1 or 2, and one or two CH.sub.2 groups
in the ring may optionally be replaced by --O--, --S--, --S(O)--,
--SO.sub.2-- or --N(R.sub.6);
[0046] wherein each R.sub.1 group is optionally substituted by one
or more of the following groups: C.sub.1-6alkyl,
C.sub.3-6cycloalkyl, halogen, nitro, hydroxy, C.sub.1-6alkyloxy,
C.sub.1-6alkylthio, aryl, arylC.sub.1-6alkyl, aryloxy, arylthio,
aminosulfonyl, or amino optionally substituted by one or two
C.sub.1-6alkyl groups, wherein each aryl group is optionally
substituted by one or more C.sub.1-6alkyl, halogen, nitro, hydroxy
or amino optionally substituted by one or two C.sub.1-6alkyl
groups, and wherein in each of the C.sub.1-6alkyl groups a
methylene group may optionally be replaced by --NHC(O)-- or
--C(O)NH--, and wherein each of the C.sub.1-6alkyl groups is
optionally substituted by one or more halogens;
[0047] R.sub.2 is selected from the following groups: 5
[0048] wherein:
[0049] n is an integer from 3 to 8;
[0050] p is an integer from 1 to 3;
[0051] q is an integer from 0 to 3;
[0052] R.sub.4 and R.sub.5 are each independently selected from
hydrogen, C.sub.1-6alkyl, arylC.sub.1-6alkyl, or amidino, wherein
each aryl group is optionally substituted by one or more
C.sub.1-6alkyl, halogen, nitro, hydroxy or amino optionally
substituted by one or two C.sub.1-6alkyl groups, and wherein each
of the C.sub.1-6alkyl groups is optionally substituted by one or
more halogens, and wherein the amidino is optionally substituted by
one to three C.sub.1-6alkyl;
[0053] R.sub.6 is hydrogen or C.sub.1-6alkyl;
[0054] wherein each R.sub.2 group is optionally substituted by one
or more C.sub.1-6alkyl, C.sub.1-6alkoxy, CN, --OH, --NH.sub.2 or
halogen;
[0055] R.sub.3 is halogen, cyano, nitro, C.sub.1-6alkyl,
C.sub.1-6alkyloxycarbonyl or aminocarbonyl, wherein each of the
C.sub.1-6alkyl groups is optionally substituted by one or more
halogens;
[0056] or a tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof,
[0057] with the proviso that the specific compounds of U.S. patent
application Publication No. 2003/0171359 A1 are excluded.
[0058] The phrase "specific compounds of U.S. patent application
Publication No. 2003/0171359 A1" means all the individual compounds
that are specifically identified by name or structure in the
disclosure of U.S. patent application Publication No. 2003/0171359
A1, herein incorporated by reference in its entirety. This
includes, but is not limited to, the following compounds:
[0059]
2-(2-naphthylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-y-
l)-5-trifluoromethyl-pyrimidine;
[0060]
2-(benzylamino)-4-(4-aminomethyl-cyclohexylmethylamino)-5-nitro-pyr-
imidine;
[0061]
2-(benzylamino)-4-(4-aminomethyl-cyclohexylmethylamino)-5-trifluoro-
methyl-pyrimidine; and
[0062]
2-(2-chlorobenzylamino)-4-(4-aminomethyl-cyclohexylmethylamino)-5-n-
itro-pyrimidine.
[0063] All the specific compounds of U.S. patent application
Publication No. 2003/0171359 A1, including the four compounds
listed above, are excluded from the present invention.
[0064] In another embodiment of the invention, there are provided
compounds of the formula (I) as described above, and wherein:
[0065] R.sub.1 is aryl-C.sub.1-4alkyl or heteroaryl-C.sub.1-4alkyl,
wherein in each of the C.sub.1-4alkyl groups a methylene group may
optionally be replaced by --NHC(O)-- or --C(O)NH--, and wherein
each of the C.sub.1-4alkyl groups is optionally substituted by an
oxo group or one or more C.sub.1-3alkyl groups wherein two alkyl
substituents on the same carbon atom of a C.sub.1-4alkyl group may
optionally be combined to form a C.sub.2-5 alkylene bridge, and
wherein the aryl group is optionally substituted on adjacent carbon
atoms by a C.sub.3-6alkylene bridge group wherein a methylene group
is optionally replaced by an oxygen, sulfur or --N(R.sub.6)-;
[0066] or R.sub.1 has the following structure: 6
[0067] wherein x and y are independently 0, 1, 2 or 3, provided
that x+y is 2 to 3, and z is 0 or 1;
[0068] wherein "heteroaryl" is defined as pyridyl, furyl, thienyl,
pyrrolyl, imidazolyl, or indolyl;
[0069] wherein each R.sub.1 group is optionally substituted by one
or more of the following groups: C.sub.1-6alkyl, Cl, Br, F, nitro,
hydroxy, CF.sub.3, --OCF.sub.3, --OCF.sub.2H, --SCF.sub.3,
C.sub.1-4alkyloxy, C.sub.1-4alkylthio, phenyl, benzyl, phenyloxy,
phenylthio, aminosulfonyl, or amino optionally substituted by one
or two C.sub.1-3alkyl groups;
[0070] R.sub.2 is selected from the following groups: 7
[0071] wherein:
[0072] n is an integer from 5 to 7;
[0073] p is an integer from 1 to 2;
[0074] q is an integer from 1 to 2;
[0075] R.sub.4 and R.sub.5 are each independently selected from
hydrogen, C.sub.1-6alkyl, arylC.sub.1-6alkyl, or amidino;
[0076] R.sub.6 is hydrogen;
[0077] R.sub.3 is Br, Cl, F, cyano or nitro;
[0078] or a tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof;
[0079] In another embodiment of the invention, there are provided
compounds of the formula (I) as described above, and wherein:
[0080] R.sub.1 is phenyl-C.sub.1-4alkyl or
naphthylC.sub.1-2alkyl,
[0081] wherein each R.sub.1 group is optionally substituted by one
or more of the following groups: methyl, Cl, Br, F, nitro, hydroxy,
CF.sub.3, --OCF.sub.3, --SCF.sub.3, C.sub.1-4alkyloxy or
C.sub.1-4alkylthio;
[0082] R.sub.2 is selected from the following groups: 8
[0083] wherein:
[0084] R.sub.4 and R.sub.5 are each independently selected from
hydrogen, C.sub.1-3 alkyl, or amidino;
[0085] R.sub.3 is Br, Cl, cyano or nitro;
[0086] or a tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof;
[0087] In another embodiment of the invention, there are provided
compounds of the formula (I) as described above, and wherein:
[0088] R.sub.1 is phenylCH.sub.2--
[0089] wherein the phenyl group is optionally substituted by one or
more of the following groups: methyl, Cl, Br, F, nitro, hydroxy,
CF.sub.3, --OCF.sub.3, --SCF.sub.3, C.sub.1-4alkyloxy or
C.sub.1-4alkylthio;
[0090] R.sub.2 is selected from the following groups: 9
[0091] R.sub.3 is nitro;
[0092] R.sub.4 and R.sub.5 are each independently selected from
hydrogen, methyl, or amidino;
[0093] or a tautomer, pharmaceutically acceptable salt, solvate, or
amino-protected derivative thereof.
[0094] In another embodiment of the invention, there are provided
compounds of the formula (I) selected from the group below:
1 ethyl 4-({[4-(aminomethyl)cyclohexyl]methyl}amin- o)-2- m/z
432.30 (M + H).sup.+ [(2-chlorobenzyl)amino]pyrimidine-5--
carboxylate 10 N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-5-nitro-N.sup.2- m/z 411.5 (M + H).sup.+
[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]pyrimidine-2,4-diamine 11
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup- .2- m/z
411.4 (M + H).sup.+ [(2S)-1,2,3,4-tetrahydronaphthalen-2-yl-
]pyrimidine-2,4-diamine 12 N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-5-nitro-N.sup.2- m/z 411.4 (M + H).sup.+
[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]pyrimidine-2,4-diamine 13
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup- .2- m/z
411.5 (M + H).sup.+ [(1S)-1,2,3,4-tetrahydronaphthalen-1-yl-
]pyrimidine-2,4-diamine 14 N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-[2-(4- m/z 419.4 (M + H).sup.+
chlorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine 15
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2- m/z
399.5 (M + H).sup.+
methylphenyl)ethyl]-5-nitropyrimidine-2,4-diamine 16
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[- 2-(3- m/z
399.5 (M + H).sup.+ methylphenyl)ethyl]-5-nitropyrimidine-
-2,4-diamine 17 N.sup.4-{[4-(aminomethyl)cyclohexyl-
]methyl}-N.sup.2-[2-(4- m/z 399.4 (M + H).sup.+
methylphenyl)ethyl]-5-nitropyrimidine-2,4-diamine 18
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2- m/z
403.4 (M + H).sup.+
fluorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine 19
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[- 2-(3- m/z
403.5 (M + H).sup.+ fluorophenyl)ethyl]-5-nitropyrimidine-
-2,4-diamine 20 N.sup.4-{[4-(aminomethyl)cyclohexyl-
]methyl}-N.sup.2-[2-(4- m/z 403.4 (M + H).sup.+
fluorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine 21
N.sup.2-(2-aminobenzyl)-N.sup.4-{[4- m/z 386.4 (M + H).sup.+
(aminomethyl)cyclohexyl]methyl}-5-nitropyrimidine-2,4-diamine 22
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3,5- m/z 431.4
(M + H).sup.+ dimethoxybenzyl)-5-nitropyrimidine-2,4-dia- mine 23
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}- -N.sup.2-[3,5- m/z
507.3 (M + H).sup.+ bis(trifluoromethyl)benzyl]--
5-nitropyrimidine-2,4-diamine 24
{3-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4- m/z 399.3 (M +
H).sup.+ yl}amino)methyl]phenyl}methane amine 25
2-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5- m/z 387.3 (M +
H).sup.+ nitropyrimidin-2-yl]amino}methyl)phenol 26
N.sup.2-(5-amino-2-chlorobenzyl)-N.sup.4-{[4- m/z 420.3 (M +
H).sup.+ (aminomethyl)cyclohexyl]methyl}-5-nitropyrimidine-2,4-dia-
mine 27 4-({[4-(aminomethyl)cyclohexyl]methyl}amino- )-2-[(2- m/z
403.40 (M + H).sup.+ chlorobenzyl)amino]pyrimidine-5-c- arboxamide
28 N.sup.4-{[4-(aminomethyl)cyclohexyl]m- ethyl}-N.sup.2-(2- m/z
378.40 (M + H).sup.+ chlorobenzyl)-5-fluorop- yrimidine-2,4-diamine
29 3-({[4-({[4-(aminomethyl)c- yclohexyl]methyl}amino)-5- m/z 532.4
(M + H).sup.+
nitropyrimidin-2-yl]amino}methyl)-N-[2-(2-methylpheny)ethyl]benzamide
30 (1S,2R)-2-({[4-({[4- m/z 393.4 (M + H).sup.+
(aminomethyl)cyclohexyl]methyl}amino)-5- nitropyrimidin-2-yl]amino-
}methyl)cyclohexanol 31 (1R,2R)-2-({[4-({[4- m/z 393.4 (M +
H).sup.+ (aminomethyl)cyclohexyl]methyl}amino)-5-
nitropyrimidin-2-yl]amino}methyl)cyclohexanol 32 methyl
4-({[4-(aminomethyl)cyclohexyl]methyl}amino)- m/z 418.40 (M +
H).sup.+ 2-[(2-chlorobenzyl)amino]pyrimidine-5-carboxylate 33
4-{[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5- m/z 484.5 (M +
H).sup.+ nitropyrimidin-2-yl]amino}-N-[2-(2-methylp-
henyl)ethyl]butanamide 34 5-{[4-({[4-(aminomethyl)c-
yclohexyl]methyl}amino)-5- m/z 498.4 (M + H).sup.+
nitropyrimidin-2-yl]amino}-N-[2-(2-methylphenyl)ethyl]pentanamide
35 6-{[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5- m/z 512.5 (M
+ H).sup.+ nitropyrimidin-2-yl]amino}-N-[2-(2-methylp-
henyl)ethyl]hexanamide 36 (1R,3R)-3-({[4-({[4-(amin-
omethyl)cyclohexyl]methyl} m/z 421.5 (M + H).sup.+
amino)-5-nitropyrimidin-2-yl]amino}methyl)-4,4-dimethylcyclohexanol
37 N.sup.4-({4-cis-[(dimethylamino)methyl]cyclohexyl}met- hyl)- m/z
449.11 (M + H).sup.+ N.sup.2-(1-naphthylmethyl)-5-nitropy-
rimidine-2,4-diamine 38 N.sup.2-[2-(methylthio)benz-
yl]-5-nitro-N.sup.4-(piperidin-4- m/z 389.16 (M + H).sup.+
ylmethyl)pyrimidine-2,4-diamine 39
5-nitro-N.sup.4-(piperidin-4-ylmethyl)-N.sup.2-{2- m/z 443.11 (M +
H).sup.+ [(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine 40
N.sup.2-(1-naphthylmethyl)-5-nitro-N.sup.4-(piperidi- n-4- m/z
393.23 (M + H).sup.+ ylmethyl)pyrimidine-2,4-diamine 41
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)- -N.sup.2-
m/z 445.5 (M + H).sup.+ [2-(methylthio)benzyl]-5-nitropyr-
imidine-2,4-diamine 42 N.sup.4-({4-[(dimethylamino)-
methyl]cyclohexyl}methyl)-5- m/z 499.5 (M + H).sup.+
nitro-N.sup.2-{2-[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine
43 N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methy- l)-N.sup.2-
m/z 449.34 (M + H).sup.+ (1-naphthylmethyl)-5-nitropyri-
midine-2,4-diamine 44 N.sup.4-{4-[(dimethylamino)me-
thyl]benzyl}-N.sup.2-[2- m/z 439.24 (M + H).sup.+
(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine 45
N.sup.4-{4-[(dimethylamino)methyl]benzyl}-5-nitro-N.sup.2-{2- m/z
493.20 (M + H).sup.+ [(trifluoromethyl)thio]benzyl}pyrimidine-2,4--
diamine 46 N.sup.4-{4-[(dimethylamino)methyl]benzyl- }-N.sup.2-(1-
m/z 443.28 (M + H).sup.+ naphthylmethyl)-5-nitropyrim-
idine-2,4-diamine 47 N.sup.4-[(1-methylpiperidin-4--
yl)methyl]-N.sup.2-[2- m/z 403.26 (M + H).sup.+
(methylthio)benzyl]-5-nitropyrimidine-2,4-diamine 48
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-nitro-N.sup.2-{2- m/z
457.24 (M + H).sup.+
[(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine 49
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-N.sup.- 2-(1- m/z 407.38
(M + H).sup.+ naphthylmethyl)-5-nitropyrimidine-2,- 4-diamine 50
N.sup.2-(2-chlorobenzyl)-N.sup.4-[(1-m-
ethylpiperidin-4-yl)methyl]- m/z 391.2 (M + H).sup.+
5-nitropyrimidine-2,4-diamine 51
N.sup.2-(2-methoxybenzyl)-N.sup.4-[(1-methylpiperidin-4- m/z 387.5
(M + H).sup.+ yl)methyl]-5-nitropyrimidine-2,4-diamine 52
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2- m/z 401.6
(M + H).sup.+ methoxybenzyl)-5-nitropyrimidine-2,4-diamine 53
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nit- ro-N.sup.2-[2-
m/z 439.6 (M + H).sup.+ (trifluoromethyl)benzyl]pyri-
midine-2,4-diamine 54 N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-(2,4- m/z 439.1 (M + H).sup.+
dichlorobenzyl)-5-nitropyrimidine-2,4-diamine 55
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3- m/z 401.6
(M + H).sup.+ methoxybenzyl)-5-nitropyrimidine-2,4-diamine 56
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[4-fluor- o-2-
m/z 457.7 (M + H).sup.+ (trifluoromethyl)benzyl]-5-nitropyrimi-
dine-2,4-diamine 57 N.sup.4-{[4-(aminomethyl)cycloh-
exyl]methyl}-N.sup.2-(3- m/z 385.6 (M + H).sup.+
methylbenzyl)-5-nitropyrimidine-2,4-diamine 58
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2- m/z
372.5 (M + H).sup.+ (pyridin-2-ylmethyl)pyrimidine-2,4-diamine 59
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3- m/z 403.2
(M - H).sup.+ chlorobenzyl)-5-nitropyrimidine-2,4-diamine 60
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.- 2-(4- m/z 403.2
(M - H).sup.+ chlorobenzyl)-5-nitropyrimidine-2,4-d- iamine 61
N.sup.4-{[4-(aminomethyl)cyclohexyl]methy- l}-N.sup.2-(4- m/z 449.1
(M - H).sup.+ bromobenzyl)-5-nitropyrimidi- ne-2,4-diamine 62
N.sup.4-{[4-(aminomethyl)cyclohex- yl]methyl}-N.sup.2-(2,4- m/z
431.4 (M + H).sup.+ dimethoxybenzyl)-5-nitropyrimidine-2,4-diamine
63 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-chloro-5-
m/z 471.2 (M - H).sup.+
(trifluoromethyl)benzyl]-5-nitropyrimidine-2,4- -diamine 64
N.sup.4-{[4-(aminomethyl)cyclohexyl]met- hyl}-N.sup.2-(2,5- m/z
437.2 (M - H).sup.+ dichlorobenzyl)-5-nitrop- yrimidine-2,4-diamine
65 N.sup.4-{[4-(aminomethyl)c-
yclohexyl]methyl}-5-nitro-N.sup.2-[2- m/z 455.5 (M + H).sup.+
(trifluoromethoxy)benzyl]pyrimidine-2,4-diamine 66
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-6-
m/z 417.2 (M - H).sup.+ methylbenzyl)-5
-nitropyrimidine-2,4-diamine 67
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup- .2-(2,3- m/z
437.1 (M - H).sup.+ dichlorobenzyl)-5-nitropyrimidine-- 2,4-diamine
68 N.sup.4-{[4-(aminomethyl)cyclohexyl]- methyl}-N.sup.2-(2- m/z
361.2 (M + H).sup.+ furylmethyl)-5-nitropyr- imidine-2,4-diamine 69
N.sup.4-{[4-(aminomethyl)cyc- lohexyl]methyl}-5-nitro-N.sup.2- m/z
377.3 (M + H).sup.+ (thien-2-ylmethyl)pyrimidine-2,4-diamine 70
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2- m/z 374 (M
+ H).sup.+ chlorobenzyl)-5-methylpyrimidine-2,4-diamine 71
N.sup.4-(6-aminohexyl)-N.sup.2-(2-chlorobenzyl)-5- m/z 378 (M +
H).sup.+ nitropyrimidine-2,4-diamine 72
N.sup.4-[4-(aminomethyl)benzyl]-N.sup.2-(2-chlorobenzyl)-5- m/z 397
(M - H).sup.+ nitropyrimidine-2,4-diamine 73
N.sup.4-(7-aminoheptyl)-N.sup.2-(2-chlorobenzyl)-5- m/z 393 (M +
H).sup.+ nitropyrimidine-2,4-diamine 74
N.sup.4-{[3-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2- m/z 404 (M
+ H).sup.+ chlorobenzyl)-5-nitropyrimidine-2,4-diamine 75
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(1-methyl- -
m/z 399.08 (M + H).sup.+ 1-phenylethyl)-5-nitropyrimidine-2,4-dia-
mine 76 4-(4,4'-bipiperidin-1-yl)-N-(2-chlorobenzyl- )-5- m/z 431
(M + H).sup.+ nitropyrimidin-2-amine 77
N.sup.2-(2-chlorobenzyl)-N.sup.4-({4- m/z 431 (M - H).sup.+
[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitropyri 78
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,5- m/z 407.5
(M + H).sup.+ difluorobenzyl)-5-nitropyrimidine-2,4-diamine 79
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.s- up.2-[4- m/z 437.6
(M + H).sup.+ (difluoromethoxy)benzyl]-5-nitropy-
rimidine-2,4-diamine 80 N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(2- m/z 415.4 (M + H).sup.+
ethoxybenzyl)-5-nitropyrimidine-2,4-diamine 81
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2- m/z
385.5 (M + H).sup.+ [(1S)-1-phenylethyl]pyrimidine-2,4-diamine 82
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2- m/z 385.4
(M + H).sup.+ methylbenzyl)-5-nitropyrimidine-2,4-diamine 83
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.- 2-(2- m/z 389.3
(M + H).sup.+ fluorobenzyl)-5-nitropyrimidine-2,4-d- iamine 84
N.sup.4-{[4-(aminomethyl)cyclohexyl]methy- l}-N.sup.2-(3-chloro-2-
m/z 423.2 (M + H).sup.+ fluorobenzyl)-5-nitropyrimidine-2,4-diamine
85 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(4-
m/z 441.6 (M + H).sup.+ pentylbenzyl)pyrimidine-2,4-diamine 86
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4- m/z 443.4
(M + H).sup.+ butoxybenzyl)-5-nitropyrimidine-2,4-diamine 87
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.- 2-(2,3- m/z
431.6 (M + H).sup.+ dimethoxybenzyl)-5-nitropyrimidine--
2,4-diamine 88 N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-(2,5- m/z 431.5 (M + H).sup.+
dimethoxybenzyl)-5-nitropyrimidine-2,4-diamine 89
N.sup.2-(2-chlorobenzyl)-N.sup.4-[7-(dimethylamino)heptyl]-5- m/z
421 (M + H).sup.+ nitropyrimidine-2,4-diamine 90
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(1,1'- m/z
447.10 (M + H).sup.+
biphenyl-2-ylmethyl)-5-nitropyrimidine-2,4-diamine 91 N.sup.4
-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2- -(4- m/z 389.06 (M +
H).sup.+ fluorobenzyl)-5-nitropyrimidine-2,4-d- iamine 92
H.sup.4-{[4-(aminomethyl)cyclohexyl]methy- l}-N.sup.2-(2,4- m/z
407.06 (M + H).sup.+ difluorobenzyl)-5-nitropy-
rimidine-2,4-diamine 93 N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-(3-fluoro-4- m/z 403.10 (M + H).sup.+
methylbenzyl)-5-nitropyrimidine-2,4-diamine 94
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3- m/z
407.02 (M + H).sup.+ difluorobenzyl)-5-nitropyrimidine-2,4-diamine
95 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-
-(2- m/z 439.90 (M + H).sup.+ chlorobenzyl)pyrimidine-2,4-diamine
96 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup- .2-(2,6- m/z
431.3 (M + H).sup.+ dimethoxybenzyl)-5-nitropyrimidine-
-2,4-diamine 97 N.sup.4-{[4-(aminomethyl)cyclohexyl-
]methyl}-N.sup.2-(2,6- m/z 407.3 (M + H).sup.+
difluorobenzyl)-5-nitropyrimidine-2,4-diamine 98
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-fluoro-3-
m/z 457.3 (M + H).sup.+
(trifluoromethyl)benzyl]-5-nitropyrimidine-2,4- -diamine 99
N.sup.4-{[4-(aminomethyl)cyclohexyl]met- hyl}-N.sup.2-(4-chloro-2-
m/z 423.2 (M + H).sup.+ fluorobenzyl)-5-nitropyrimidine-2,4-diamine
100 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(1-
m/z 397.04 (M + H).sup.+ phenylcyclopropyl)pyrimidine-2,4-diamine
101 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2- -[1-(2-
m/z 433.04 (M + H).sup.+ chlorophenyl)-1-methylethyl]-5-nit-
ropyrimidine-2,4-diamine 102
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3- m/z 413.4
(M + H).sup.+
dihydro-1-benzofuran-5-ylmethyl)-5-nitropyrimidine-2,4-di- amine
103 N.sup.4-{[4-(aminomethyl)cyclohexyl]methy- l}-N.sup.2-[(1,5-
m/z 388.4 (M + H).sup.+ dimethyl-1H-pyrrol-2-yl)m-
ethyl]-5-nitropyrimidine-2,4-diamine 104
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2- m/z 450.9
(M + H).sup.+ bromobenzyl)-5-nitropyrimidine-2,4-diamine 105
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3- m/z
399.14 (M + H).sup.+ dimethylbenzyl)-5-nitropyrimidine-2,4-diamine
106 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.- sup.2-(2,4- m/z
399.18 (M + H).sup.+ dimethylbenzyl)-5-nitropyrimid-
ine-2,4-diamine 107 N.sup.4-{[4-(aminomethyl)cycloh-
exyl]methyl}-N.sup.2-(2,5- m/z 399.13 (M + H).sup.+
dimethylbenzyl)-5-nitropyrimidine-2,4-diamine 108
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-fluoro-5-
m/z 457.17 (M + H).sup.+
(trifluoromethyl)benzyl]-5-nitropyrimidine-2,- 4-diamine 109
N.sup.4-{[4-(aminomethyl)cyclohexyl]m- ethyl}-N.sup.2-[2- m/z
417.02 (M + H).sup.+ (methylthio)benzyl]-5-n-
itropyrimidine-2,4-diamine 110
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-{2- m/z
470.96 (M + H).sup.+ [(trifluoromethyl)thio]benzyl}pyrimidine-2,4--
diamine 111 N.sup.4-{[4-(aminomethyl)cyclohexyl]met-
hyl}-N.sup.2-(3- m/z 389.05 (M + H).sup.+
fluorobenzyl)-5-nitropyri- midine-2,4-diamine 112
N.sup.4-{[4-(aminomethyl)cyc- lohexyl]methyl}-N.sup.2-(6-chloro-2-
m/z 436.98 (M + H).sup.+
fluoro-3-methylbenzyl)-5-nitropyrimidine-2,4-diamine 113
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-6-
m/z 436.99 (M + H).sup.+ fluoro-3-methylbenzyl)-5-nitropyrimidine--
2,4-diamine 114 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}--
N.sup.2-2-naphthyl- m/z 407.2 (M + H).sup.+
5-nitropyrimidine-2,4-d- iamine 115
N.sup.4-{[4-(aminomethyl)cyclohexyl]meth- yl}-N.sup.2-(1- m/z
421.11 (M + H).sup.+ naphthylmethyl)-5-nitropyr-
imidine-2,4-diamine 116 N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-[2-fluoro-4- m/z 457.5 (M + H).sup.+
(trifluoromethyl)benzyl]-5-nitropyrimidine-2,4-diamine 117
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-chloro-2-
m/z 419.4 (M + H).sup.+ methylbenzyl)-5-nitropyrimidine-2,4-diamin-
e 118 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N-
.sup.2-(5-chloro-2- m/z 419.3 (M + H).sup.+
methylbenzyl)-5-nitropy- rimidine-2,4-diamine 119
N.sup.4-{[4-(aminomethyl)cyclohexyl- ]methyl}-N.sup.2-(3-chloro-2-
m/z 419.3 (M + H).sup.+ methylbenzyl)-5-nitropyrimidine-2,4-diamine
120
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[5-fluoro-2-
m/z 457.12 (M + H).sup.+
(trifluoromethyl)benzyl]-5-nitropyrimidine-2,- 4-diamine 121
N.sup.4-{[4-(aminomethyl)cyclohexyl]m- ethyl}-N.sup.2-(5-chloro-2-
m/z 423.01 (M + H).sup.+
fluorobenzyl)-5-nitropyrimidine-2,4-diamine 122
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3- m/z
421.15 (M + H).sup.+
difluoro-4-methylbenzyl)-5-nitropyrimidine-2,4-diamine 123
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup- .2-(5-fluoro-2-
m/z 403.10 (M + H).sup.+ methylbenzyl)-5-nitropyrim-
idine-2,4-diamine 124 N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-1-naphthyl- m/z 407.0 (M + H).sup.+
5-nitropyrimidine-2,4-diamine 125
{4-trans-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin- m/z 406.05
(M + H).sup.+ 4-yl}amino)methyl]cyclohexyl}methanol 126
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2- m/z
474.0 (M + H).sup.+ (2,5-dichlorobenzyl)pyrimidine-2,4-diamine 127
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-brom- o-N.sup.2- m/z
473.30 (M + H).sup.+ (2,4-dichlorobenzyl)pyrimidine-- 2,4-diamine
128 N.sup.4-{[4-(aminomethyl)cyclohexyl-
]methyl}-5-bromo-N.sup.2-(2- m/z 484.10 (M + H).sup.+
bromobenzyl)pyrimidine-2,4-diamine 129
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2- m/z 372 (M +
H).sup.+ (cyclohexylmethyl)-5-nitropyrimidine-2,4-diamine 130
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(- 2- m/z 421.1
(M + H).sup.+ naphthylmethyl)-5 -nitropyrimidine-2,4-diamine 131
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-[2- m/z
489.90 (M + H).sup.+ (trifluoromethoxy)benzyl]pyrimidine-2,4-diami-
ne 132 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}--
5-bromo-N.sup.2-[2- m/z 473.20 (M + H).sup.+
(trifluoromethyl)benzyl]pyrimidine-2,4-diamine 133
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2- m/z 437 (M
+ H).sup.+ (difluoromethoxy)benzyl]-5-nitropyrimidine-2,4-diamine
134 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup- .2-[3- m/z
437.3 (M + H).sup.+ (difluoromethoxy)benzyl]-5-nitropyri-
midine-2,4-diamine 135 N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-N.sup.2-(2-chloro-4- m/z 423.3 (M + H).sup.+
fluorobenzyl)-5-nitropyrimidine-2,4-diamine 136
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro- m/z
441.2 (M + H).sup.+
3,6-difluorobenzyl)-5-nitropyrimidine-2,4-diamine 137
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nit- ro-N.sup.2- m/z
425.3 (M + H).sup.+ (2,3,5-trifluorobenzyl)pyrimidi- ne-2,4-diamine
138 N.sup.4-{[4-(aminomethyl)cyclohe- xyl]methyl}-5-nitro-N.sup.2-
m/z 443.3 (M + H).sup.+
(2,3,4,5-tetrafluorobenzyl)pyrimidine-2,4-diamine 139
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2- m/z
385.3 (M + H).sup.+ [(1R)-1-phenylethyl]pyrimidine-2,4-diamine 140
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-2- ,3-dihydro-
m/z 397.3 (M + H).sup.+ 1H-inden-2-yl-5-nitropyrimidine-
-2,4-diamine 141 N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-N.sup.2-[(1S)-2,3- m/z 397.4 (M + H).sup.+
dihydro-1H-inden-1-yl]-5-nitropyrimidine-2,4-diamine 142
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[(1R)-2,3- m/z
397.4 (M + H).sup.+ dihydro-1H-inden-1-yl]-5-nitropyrimidine-2,4-d-
iamine 143 N.sup.4-{[4-(aminomethyl)cyclohexyl]meth-
yl}-N.sup.2-(4-chloro-1- m/z 441.3 (M + H).sup.+
naphthyl)-5-nitropyrimidine-2,4-diamine 144
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-methoxy- m/z
437.3 (M + H).sup.+ 2-naphthyl)-5-nitropyrimidine-2,4-diamine 145
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup- .2- m/z
408.3 (M + H).sup.+ quinolin-6-ylpyrimidine-2,4-diamine 146
N.sup.4-{[4-trans-(aminomethyl)cyclohexyl]methyl}-- N.sup.2-(2,5-
m/z 439.3 (M + H).sup.+ dichlorobenzyl)-5-nitropyrimi-
dine-2,4-diamine 147 N.sup.4-{[4-trans-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-(2,3- m/z 439.3 (M + H).sup.+
dichlorobenzyl)-5-nitropyrimidine-2,4-diamine 148
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2- m/z
419.4 (M + H).sup.+
chlorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine 149
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[- 2-(3- m/z
419.4 (M + H).sup.+ chlorophenyl)ethyl]-5-nitropyrimidine-
-2,4-diamine 150 N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-N.sup.2-(2-chloro-6- m/z 497.4 (M + H).sup.+
phenoxybenzyl)-5-nitropyrimidine-2,4-diamine 151
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-2- m/z
441.10 (M + H).sup.+ naphthylpyrimidine-2,4-diamine 152
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-(1- m/z
455.20 (M + H).sup.+ naphthylmethyl)pyrimidine-2,4-diamine 153
H.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N- .sup.2- m/z
372.3 (M + H).sup.+ (pyridin-3-ylmethyl)pyrimidine-2,4-- diamine
154 H.sup.4-{[4-(aminomethyl)cyclohexyl]met- hyl}amino)-2-[(2- m/z
385.40 (M + H).sup.+ chlorobenzyl)amino]pyrim- idine-5-carbonitrile
155 N.sup.4-{[4-(aminomethyl)c- yclohexyl]methyl}-N.sup.2-[4- m/z
414.4 (M + H).sup.+
(dimethylamino)benzyl]-5-nitropyrimidine-2,4-diamine 156
N.sup.4-{[4-trans-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2- m/z
451.2 (M + H).sup.+ bromobenzyl)-5-nitropyrimidine-2,4-diamine 157
N.sup.4-(7-aminoheptyl)-N.sup.2-(2-bromobenzyl)-5- m/z 437.3 (M +
H).sup.+ nitropyrimidine-2,4-diamine 158
N.sup.4-(7-aminoheptyl)-N.sup.2-(2,5-dichlorobenzyl)-5- m/z 427.3
(M + H).sup.+ nitropyrimidine-2,4-diamine 159
N-({4-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4- m/z 446.9 (M
+ H).sup.+ yl}amino)methyl]cyclohexyl}methyl)guanidine 160
N.sup.2-(3-aminobenzyl)-N.sup.4-{[4- m/z 386.4 (M + H).sup.+
(aminomethyl)cyclohexyl]methyl}-5-nitropyrimidine-2,4-dia- mine 161
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl- }-5-nitro-N.sup.2-(2-
m/z 416.5 (M + H).sup.+ nitrobenzyl)pyrimidine-2,4-diamine 162
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2- m/z
463.3 (M + H).sup.+
bromophenyl)ethyl]-5-nitropyrimidine-2,4-diamine 163
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(- 2- m/z 439.0
(M + H).sup.+ bromobenzyl)-5-chloropyrimidine-2,4-diam- ine 164
(4-{[(2-{[2-(1H-indol-3-yl)ethyl]amino}-5-n- itropyrimidin- m/z
425.3 (M + H).sup.+ 4-yl)amino]methyl}cyclohexyl- )methanaminium
chloride 165 N-({3-[({2-[(2-chlorobe-
nzyl)amino]-5-nitropyrimidin-4- m/z 447.4 (M + H).sup.+
yl}amino)methyl]cyclohexyl}methyl)guanidine 166
3-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5- m/z 387.4 (M +
H).sup.+ nitropyrimidin-2-yl]amino}methyl)phenol 167
(4-{[(2-{[2-(1H-imidazol-4-yl)ethyl]amino}-5-nitropyrimidin-4- m/z
375 (M + H).sup.+ yl)amino]methyl}cyclohexyl)methanaminium chloride
168 N.sup.2-(2-chlorobenzyl)-N.sup.4-({4-- cis- m/z 433.2 (M +
H).sup.+ [(dimethylamino)methyl]cyclohexyl}meth-
yl)-5-nitropyrimidine-2,4-diamine 169
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-chloro-N.sup.2-(2-
m/z 395.10 (M + H).sup.+ chlorobenzyl)pyrimidine-2,4-diamine 170
N.sup.2-(2-chlorobenzyl)-5-nitro-N.sup.4-(piperidin-4- - m/z 377.5
(M + H).sup.+ ylmethyl)pyrimidine-2,4-diamine 171
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N- .sup.2-(2-
m/z 385.5 (M + H).sup.+ phenylethyl)pyrimidine-2,4-diami- ne 172
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-- 5-nitro-N.sup.2-(3-
m/z 399.4 (M + H).sup.+ phenylpropyl)pyrimidine- -2,4-diamine 173
N.sup.4-{[4-(aminomethyl)cyclohexy- l]methyl}-5-nitro-N.sup.2-(4-
m/z 413.5 (M + H).sup.+ phenylbutyl)pyrimidine-2,4-diamine 174
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(2- m/z
399.5 (M + H).sup.+ phenylpropyl)pyrimidine-2,4-diamine 175
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(4- m/z
415.5 (M + H).sup.+ methoxyphenyl)ethyl]-5-nitropyrimidine-2,4-dia-
mine 176 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl-
}-N.sup.2-[2-(3- m/z 415.5 (M + H).sup.+
methoxyphenyl)ethyl]-5-nit- ropyrimidine-2,4-diamine 177
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(2- m/z
415.5 (M + H).sup.+
methoxyphenyl)ethyl]-5-nitropyrimidine-2,4-diamine 178
4-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4- m/z 419.1 (M +
H).sup.+ yl}amino)methyl]piperidine-1-carboximidami- de 179
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-- N.sup.2-(3,5- m/z
439.1 (M + H).sup.+ dichlorobenzyl)-5-nitropyrimi- dine-2,4-diamine
180 N4-(5-aminopentyl)-N2-(2-chlor-
obenzyl)-5-nitropyrimidine-2,4-diamine 181
2-(benzylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-
c]pyridin-5-yl)-5-trifluoromethyl-pyrimidine 182
2-(4-chlorobenzylamino)-4-(1,4,6,7-tetrahydro-
imidazo[4,5-c]pyridin-5-yl)-5-nitro-pyrimidine 183
2-(2-chlorobenzylamino)-4-(1,4,6,7-tetrahydro-
imidazo[4,5-c]pyridin-5-yl)-5-nitro-pyrimidine 184
2-(benzylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-
c]pyridin-5-yl)-5-nitro-pyrimidine 185
[0095] In another embodiment, there are provided compounds selected
from the group below:
2 N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup-
.2-[(2R)-1,2,3,4- tetrahydronaphthalen-2-yl]pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(4-chloroph-
enyl)ethyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(3-methylphenyl)et-
hyl]-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-[2-(4-methylphenyl)ethyl]-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-[2-(3-fluorophenyl)ethyl]-5-
nitropyrimidine-2,4-diam- ine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(4-fluor-
ophenyl)ethyl]-5- nitropyrimidine-2,4-diamine
(1R,3R)-3-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidi-
n-2- yl]amino}methyl)-4,4-dimethylcyclohexanol
N.sup.4-({4-cis-[(dimethylamino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naph-
thylmethyl)-5- nitropyrimidine-2,4-diamine
N.sup.2-[2-(methylthio)benzyl]-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyri-
midine-2,4-diamine
5-nitro-N.sup.4-(piperidin-4-ylmethyl)-N.sup.2-{-
2-[(trifluoromethyl)thio]benzyl} pyrimidine-2,4- diamine
N.sup.2-(1-naphthylmethyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyrimidi-
ne-2,4-diamine
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl-
)-N.sup.2-[2-(methylthio)benzyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitro-N.sup.2--
{2- [(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthyl-
methyl)-5- nitropyrimidine-2,4-diamine
N.sup.4-{4-[(dimethylamino)methyl]benzyl}-N.sup.2-[2-(methylthio)benzyl]--
5-nitropyrimidine- 2,4-diamine N.sup.4-{4-[(dimethylamino)me-
thyl]benzyl}-5-nitro-N.sup.2-{2-[(trifluoromethyl)thio]
benzyl}pyrimidine-2,4-diamine N.sup.4-[(1-methylpiperidin-4-yl)met-
hyl]-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4- diamine
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-nitro-N.sup.2-{2-[(trif-
luoromethyl)thio] benzyl}pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-methoxybenzyl)-5-n-
itropyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohe-
xyl]methyl}-5-nitro-N.sup.2-[2-
(trifluoromethyl)benzyl]pyrimidine-- 2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,-
4-dichlorobenzyl)-5-nitropyrimidine- 2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[4-fluoro-2-(trifluor-
omethyl)benzyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-methylbenzyl)-5-ni-
tropyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(3-chlorobenzyl)-5-nitropyrimidine-2,4- diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-bromobenzyl-
)-5-nitropyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-N.sup.2-[2-chloro-5-(trifluoromethyl)benzyl]-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(2,5-dichlorobenzyl)-5-nitropyrimidine- 2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-[2-(trif-
luoromethoxy) benzyl]pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-6-methylben-
zyl)-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobenzyl)-5-nitropyrimidine-
2,4-diamine N.sup.4-{[3-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-
-chlorobenzyl)-5-nitropyrimidine-2,4- diamine
N.sup.2-(2-chlorobenzyl)-N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}me-
thyl)-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-N.sup.2-(2,5-difluorobenzyl)-5-nitropyrimidine-
2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(-
2-ethoxybenzyl)-5-nitropyrimidine-2,4- diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-methylbenzyl)-5-ni-
tropyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(2-fluorobenzyl)-5-nitropyrimidine-2,4- diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-chloro-2-fl-
uorobenzyl)-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(1,1'-biphenyl-2-ylme-
thyl)-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-N.sup.2-(2,4-difluorobenzyl)-5-nitropyrimidine-
2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(-
2,3-difluorobenzyl)-5-nitropyrimidine- 2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,6-difluorobenzyl)--
5-nitropyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-[2-fluoro-3-(trifluoromethyl)benzyl]-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(4-chloro-2-fluorobenzyl)-5-
nitropyrimidine-2,4-diam- ine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-bromoben-
zyl)-5-nitropyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-(2,3-dimethylbenzyl)-5-nitropyrimidine-
2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-
-(methylthio)benzyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-{2-[(trifluor-
omethyl)thio]benzyl} pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-fluorobenzyl)-5-ni-
tropyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(6-chloro-2-fluoro-3-methylbenzyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(2-chloro-6-fluoro-3-methylbenzyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-2-naphthyl-5-nitropyrimidine-2,4- diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(1-naphthylmethyl)-5--
nitropyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cycloh-
exyl]methyl}-N.sup.2-(4-chloro-2-methylbenzyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(5-chloro-2-methylbenzyl)-5-
nitropyrimidine-2,4-diam- ine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(3-chloro-2-
-methylbenzyl)-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[5-fluoro-2-(trifluor-
omethyl)benzyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(5-chloro-2-fluoroben-
zyl)-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-(2,3-difluoro-4-methylbenzyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(5-fluoro-2-methylbenzyl)-5-
nitropyrimidine-2,4-diam- ine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-(2,-
5-dichlorobenzyl)pyrimidine- 2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-(2-bromobenzy-
l) pyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohex-
yl]methyl}-N.sup.2-(cyclohexylmethyl)-5-nitropyrimidine-
2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.-
sup.2-[2- (trifluoromethyl)benzyl]pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(difluoromethoxy)b-
enzyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chloro-4-fluoroben-
zyl)-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl-
)cyclohexyl]methyl}-N.sup.2-(2-chloro-3,6-difluorobenzyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-5-nitro-N.sup.2-(2,3,5-trifluorobenzyl)pyrimidine-
2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-2,-
3-dihydro-1H-inden-2-yl-5- nitropyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(4-chloro-1-naphthyl)-
-5-nitropyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cyc-
lohexyl]methyl}-N.sup.2-(4-methoxy-2-naphthyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-5-nitro-N.sup.2-quinolin-6-ylpyrimidine-2,4- diamine
N.sup.4-{[4-trans-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobe-
nzyl)-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethy-
l)cyclohexyl]methyl}-N.sup.2-[2-(2-chlorophenyl)ethyl]-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-[2-(3-chlorophenyl)ethyl]-5-
nitropyrimidine-2,4-diam- ine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-bromo-N.sup.2-2-n-
aphthylpyrimidine-2,4- diamine 4-({[4-(aminomethyl)cyclohexy-
l]methyl}amino)-2-[(2-chlorobenzyl) amino]pyrimidine-5-carbonitrile
N.sup.4-{[4--trans-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-brom-
obenzyl)-5- nitropyrimidine-2,4-diamine
N.sup.4-(7-aminoheptyl)-N.sup.2-(2-bromobenzyl)-5-nitropyrimidine-2,4-dia-
mine
N.sup.4-(7-aminoheptyl)-N.sup.2-(2,5-dichlorobenzyl)-5-nitropy-
rimidine-2,4-diamine
N-({4-[({2-[(2-chlorobenzyl)amino]-5-nitropyri- midin-4-
yl}amino)methyl]cyclohexyl}methyl)guanidine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(2-nitrobenzy-
l)pyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-N.sup.2-[2-(2-bromophenyl)ethyl]-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(2-bromobenzyl)-5-chloropyrimidine-2,4- diamine
N-({3-[({2-[(2-chlorobenzyl)amino]-5-nitropyrimidin-4-
yl}amino)methyl]cyclohexyl}methyl)guanidine
3-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidin-2-
yl]amino}methyl)phenol N.sup.2-(2-chlorobenzyl)-N.sup.4-({4-cis-
-[(dimethylamino)methyl]cyclohexyl}methyl)-5-
nitropyrimidine-2,4-diamine N.sup.2-(2-chlorobenzyl)-5-nitro-N.sup-
.4-(piperidin-4-ylmethyl)pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-5-nitro-N.sup.2-(2-phenylethy-
l)pyrimidine-2,4- diamine N.sup.4-{[4-(aminomethyl)cyclohexy-
l]methyl}-5-nitro-N.sup.2-(4-phenylbutyl)pyrimidine-2,4-
diamine
[0096] In yet another embodiment, there are provided compounds
selected from the group below:
3 N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.s-
up.2-(1-naphthylmethyl)-5- nitropyrimidine-2,4-diamine
N.sup.2-[2-(methylthio)benzyl]-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyri-
midine-2,4-diamine
5-nitro-N.sup.4-(piperidin-4-ylmethyl)-N.sup.2-{-
2-[(trifluoromethyl)thio] benzyl}pyrimidine-2,4- diamine
N.sup.2-(1-naphthylmethyl)-5-nitro-N.sup.4-(piperidin-4-ylmethyl)pyrimidi-
ne-2,4-diamine
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl-
)-N.sup.2-[2-(methylthio)benzyl]-5- nitropyrimidine-2,4-diamine
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-5-nitro-N.sup.2--
{2- [(trifluoromethyl)thio]benzyl}pyrimidine-2,4-diamine
N.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-N.sup.2-(1-naphthyl-
methyl)-5- nitropyrimidine-2,4-diamine
N.sup.4-{4-[(dimethylamino)methyl]benzyl}-N.sup.2-[2-(methylthio)benzyl]--
5-nitropyrimidine- 2,4-diamine N.sup.4-{4-[(dimethylamino)me-
thyl]benzyl}-5-nitro-N.sup.2-{2-[(trifluoromethyl)thio]
benzyl}pyrimidine-2,4-diamine N.sup.4-[(1-methylpiperidin-4-yl)met-
hyl]-N.sup.2-[2-(methylthio)benzyl]-5-nitropyrimidine-2,4- diamine
N.sup.4-[(1-methylpiperidin-4-yl)methyl]-5-nitro-N.sup.2-{2-[(trif-
luoromethyl)thio] benzyl}pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-methoxybenzyl)-5-n-
itropyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohe-
xyl]methyl}-5-nitro-N.sup.2-[2-(trifluoromethoxy)
benzyl]pyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]-
methyl}-N.sup.2-(2,3-dichlorobenzyl)-5-nitropyrimidine- 2,4-diamine
N.sup.4-{[3-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2-chlorobenzy-
l)-5-nitropyrimidine-2,4- diamine N.sup.2-(2-chlorobenzyl)-N-
.sup.4-({4-[(dimethylamino)methyl]cyclohexyl}methyl)-5-
nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cyclohexyl]me-
thyl}-N.sup.2-(2-bromobenzyl)-5-nitropyrimidine-2,4- diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-[2-(methylthio)benzyl-
]-5- nitropyrimidine-2,4-diamine N.sup.4-{[4-(aminomethyl)cy-
clohexyl]methyl}-5-nitro-N.sup.2-{2-
[(trifluoromethyl)thio]benzyl}- pyrimidine-2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}--
N.sup.2-(1-naphthylmethyl)-5-nitropyrimidine- 2,4-diamine
N.sup.4-{[4-(aminomethyl)cyclohexyl]methyl}-N.sup.2-(2,3-dichlorobenzyl)--
5-nitropyrimidine- 2,4-diamine N.sup.4-{[4-(aminomethyl)cycl-
ohexyl]methyl}-N.sup.2-(2-bromobenzyl)-5-nitropyrimidine-2,4-
diamine N.sup.2-(2-chlorobenzyl)-5-nitro-N.sup.4-(piperidin-4-ylme-
thyl)pyrimidine-2,4-diamine
[0097] As discussed above, any compound of this invention may occur
as individual geometric isomers, stereoisomers, enantiomers,
diastereomers, racemates, racemic or non-racemic mixtures of
stereoisomers, and mixtures of diastereomers, All such isomeric
forms, and mixtures thereof, of these compounds are expressly
included in the present invention. Each stereogenic carbon may be
in the R or S configuration, or a combination of
configurations.
[0098] Some of the compounds of the present invention can exist in
more than one tautomeric form. The invention also includes all such
tautomers.
General Synthetic Methods
[0099] The compounds of the invention may be prepared by the
methods described below. In each of the schemes below, the groups
R.sub.1, R.sub.2 and R.sub.3 are as defined above for general
formula I unless noted otherwise. Optimum reaction conditions and
reaction times may vary depending on the particular reactants used.
Unless otherwise specified, solvents, temperatures, pressures and
other reaction conditions may be readily selected by one of
ordinary skill in the art. Specific procedures are provided in the
Synthetic Examples section. Typically, reaction progress may be
monitored by thin layer chromatography (TLC) if desired.
Intermediates and products may be purified by chromatography on
silica gel and/or recrystallization. Starting materials and
reagents are either commercially available or may be prepared by
one skilled in the art using methods described in the chemical
literature.
[0100] Compounds of formula (I) may be prepared as illustrated in
Scheme I and described below. 186
[0101] As illustrated above, a 2,4-dihalopyrimidine (II),
preferably a 2,4-dichloropyrimidine, is reacted with about one
equivalent of an amine (R'R"NH) in the presence of a base, such as
triethylamine, in a suitable solvent, such as EtOH, to provide
intermediate III. The reaction is carried out preferably at about
0.degree. C. to about room temperature. Intermediate III is then
reacted with a second amine R.sub.1NH.sub.2 in a suitable solvent,
such as EtOH, to provide the desired I. The reaction is preferably
heated to about the reflux temperature of the solvent. For
intermediates III having R.sub.3 groups that are less electron
withdrawing than NO.sub.2, such as R.sub.3=F, Cl, CN or CO.sub.2Et,
the reaction is preferably carried out in a sealed vessel in a
microwave reactor at about 140.degree. C.
[0102] If R.sub.2 contains a second amine group, (i.e., in the R'
and/or R" groups in Scheme I above) the second amine is preferably
protected with a suitable amino-protecting group, for example with
a Boc-group, prior to reaction with intermediate II, and the amine
is deprotected after reaction of the pyrimidine intermediate with
R.sub.1NH.sub.2. For example, in the case of
1,4-cyclohexanebis(methylamine) as illustrated in Scheme II, the
mono-Boc-protected diamine is reacted with II as described above.
The resulting intermediate IV is then reacted with R.sub.1NH.sub.2
as described above, and the Boc-protected intermediate V is then
deprotected by treatment with acid to provide the desired compound
of formula (I). 187
[0103] In a variation illustrated in Scheme III, if R.sub.3 is
NO.sub.2, intermediate II may be reacted with a thiocyanate salt,
such as potassium thiocyanate, in a suitable solvent, such as EtOH,
to produce VI. Intermediate VI is reacted with R.sub.1NH.sub.2 in a
suitable solvent, such as EtOH, and in the presence of a base, such
as triethylamine, to provide VII. Intermediate VII may then be
reacted with an amine R'R"NH in a suitable solvent, such as EtOH or
methylene chloride, to provide the desired compound of formula I
188
[0104] Substituents R.sub.1, R.sub.2 and R.sub.3 may be further
modified by methods known in the art to obtain additional compounds
of formula (I). Some of these modifications are illustrated in the
synthetic examples below.
[0105] In order that this invention be more fully understood, the
following examples are set forth. These examples are for the
purpose of illustrating embodiments of this invention, and are not
to be construed as limiting the scope of the invention in any way.
Starting materials used are either commercially available or easily
prepared from commercially available materials by those skilled in
the art.
SYNTHETIC EXAMPLES
Example 1
[0106] Synthesis of
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-N.sup.2-(2-ch-
loro-benzyl)-5-fluoro-pyrimidine-2,4-diamine 189
[0107] Di-tert-butyl dicarbonate (44.00 g, 201 mmol) was added to a
solution of 1,4-cyclohexanebis(methylamine) cis+trans (14.35 g, 142
mmol) in CH.sub.2Cl.sub.2 at room temperature. After stirring at
room temperature for 16 h, the reaction mixture was concentrated in
vacuo to provide
[4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]-carbamic
acid tert-butyl ester as a white powder 34.32 g, 99%, m/z
calculated for C.sub.18H.sub.34N.sub.2O.sub.4: 342.5, found: 343.3
(M+H).sup.+.
[0108] To a solution of
[4-(tert-butoxycarbonylamino-methyl)-cyclohexylmet- hyl]-carbamic
acid tert-butyl ester (11.00 g, 32 mmol) dissolved in 2:1
CHC.sub.3:EtOH at room temperature was added 4.0 M HCl/dioxane
(16.1 mL). The mixture was stirred at room temperature for 4 h then
concentrated in vacuo to provide a crude white solid. The crude
material was purified by silica gel chromatography using a gradient
elution of 10-50% (2% NH.sub.4OH, 18% MeOH, 80%
CH.sub.2Cl.sub.2)/CH.sub.2Cl.sub.2. The product-containing
fractions were combined and concentrated in vacuo to provide
(4-aminomethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester as
a white powder 3.62 g, 47%, m/z calculated for
C.sub.13H.sub.26N.sub.2- O2: 242.4, found: 243.3 (M+H).sup.30 .
[0109] To a solution of (4-aminomethyl-cyclohexylmethyl)-carbamic
acid tert-butyl ester (606 mg, 2.5 mmol) and triethylamine (0.7 mL,
5.0 mmol) dissolved in EtOH at 0.degree. C., was added
2,4-dichloro-5-fluoropyrimid- ine (835 mg, 5.0 mmol). The reaction
mixture was warmed to room temperature and stirred for 18 h. The
mixture was then concentrated in vacuo and the crude product was
purified by silica gel chromatography using 0-20% EtOAc/hexanes.
The product-containing fractions were combined and concentrated in
vacuo to provide {4-[(2-chloro-5-fluoro-pyrimidinyl-4-
-amino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl ester as
a white solid 495 mg, 53%, m/z calculated for
C.sub.17H.sub.26ClFN.sub.4O2: 372.9, found: 373.4 (M+H).sup.+.
[0110]
{4-[(2-chloro-5-fluoro-pyrimidinyl-4-amino)-methyl]-cyclohexylmethy-
l}-carbamic acid tert-butyl ester and 2-chlorobenzylamine were
added to a microwave reaction tube and dissolved in absolute EtOH
(2 mL). The reaction mixture was heated 140.degree. C. in a
microwave reactor for 5 h. and then cooled to room temperature. The
reaction mixture was then concentrated in vacuo, dissolved in
CHC.sub.3, and purified by silica gel chromatography using 10-20%
EtOAc/hexanes. The product-containing fractions were combined and
concentrated in vacuo to provide
{4-[(2-(2-chlorobenzylamino)-5-fluoro-pyrimidinyl-4-amino)-methyl]-cycloh-
exylmethyl}-carbamic acid tert-butyl ester as a colorless foam 102
mg, 53%, m/z calculated for C.sub.24H.sub.33ClFN.sub.5O2: 478.0,
found: 479.8 (M+H).sup.30 .
[0111] To a solution of
{4-[(2-(2-chlorobenzylamino)-5-fluoro-pyrimidinyl--
4-amino)-methyl]-cyclohexylmethyl }-carbamic acid tert-butyl ester
(102 mg, 0.213 mmol) dissolved in 2:1 CHCl.sub.3:EtOH at room
temperature was added 4.0 M HCl/dioxane (5.0 mL). The mixture was
stirred at room temperature for 2 h then concentrated in vacuo to
provide a crude white powder. The crude material was purified by
silica gel chromatography using a gradient elution of 10-50% (2%
NH.sub.4OH, 18% MeOH, 80% CH.sub.2Cl.sub.2)/CH.sub.2Cl.sub.2. The
product-containing fraction combined and concentrated in vacuo to
provide the title compound as a colorless foam 76 mg, 94%, m/z
calculated for C.sub.19H.sub.25ClFN.sub.5: 377.9, found: 378.4
(M+H).sup.+.
Example 2
[0112] Synthesis of
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-5-chloro-N.su-
p.2-(2-chloro-benzyl)-pyrimidine-2,4-diamine 190
[0113] This compound was prepared from 2,4,5-trichloropyrimidine
using the same procedures described in Example 1 to provide the
title compound as a white solid 41 mg, 30%, m/z calculated for
C.sub.19H.sub.25Cl.sub.2N.sub.- 5: 394.4, found: 395.3
(M+H).sup.+.
Example 3
[0114] Synthesis of
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-5-bromo-N.sup-
.2-(2-chloro-benzyl)-pyrimidine-2,4-diamine 191
[0115] This compound was prepared from
5-bromo-2,4-dichloropyrimidine using the same procedures described
in Example 1 to provide the title compound as a white solid 18 mg,
22%, m/z calculated for C.sub.19H.sub.25BrClN.sub.5: 438.8, found:
439.9 (M+H).sup.+.
Example 4
[0116] Synthesis of
4-[(4-aminomethyl-cyclohexylmethyl)-amino]-2-(2-chloro-
-benzylamino)-pyrimidine-5-carbonitrile 192
[0117] A mixture of tris(dibenzylidenacetone)-dipalladium(0) (26
mg, 0.028 mmol), zinc cyanide (20 mg, 169 mmol),
1,1'-bis(diphenylphosphino)-ferroc- ene (19 mg, 0.034 mmol) and
{4-[(2-(2-chlorobenzylamino)-5-bromo-pyrimidin-
yl-4-amino)-methyl]-cyclohexylmethyl}-carbamic acid tert-butyl
ester (155 mg, 0.288 mmol) in a pressure tube was evacuated and
filled with N.sub.2 several times. The mixture was then dissolved
in degassed DMF (2 mL) and heated to 130.degree. C. under an
N.sub.2 atmosphere for 18 h. The mixture was then concentrated in
vacuo, dissolved in CH.sub.2Cl.sub.2, and filtered through a pad of
diatomaceous earth. The filtrate was then concentrated in vacuo and
purified by silica gel chromatography using 0-25% EtOAc/hexanes.
The product-containing fractions were combined and concentrated in
vacuo to provide the desired cyano intermediate as a pale yellow
foam 65 mg, 47%, m/z calculated for C.sub.25H.sub.33ClN.sub.6O.sub-
.2: 485.034, found: 486.9 (M+H).sup.+.
[0118] Compound 4 was prepared from the above cyano intermediate by
treating with 4.0 M HCl/dioxane using the same deprotection
procedure previously described for Example 1. The title compound
was isolated as a pale yellow foam 27 mg, 59%, m/z calculated for
C.sub.20H.sub.25ClN.sub.6- : 384.9, found: 385.4 (M+H).sup.+.
Example 5
[0119] Synthesis of
4-[(4-aminomethyl-cyclohexylmethyl)-amino]-2-(2-chloro-
-benzylamino)-pyrimidine-5-carboxylic acid ethyl ester 193
[0120] This compound was prepared from
2,4-dichloro-5-carboethoxypyrimidin- e using the same procedures
described in Example 1. The title compound was isolated as a white
powder, m/z calculated for C.sub.22H.sub.30ClN.sub.5O- .sub.2:
431.9, found: 432.3 (M+H).sup.+.
Example 6
[0121] Synthesis of
4-[(4-aminomethyl-cyclohexylmethyl)-amino]-2-(2-chloro-
-benzylamino)-pyrimidine-5-carboxylic acid 194
[0122] A solution of LiOH (240 mg, 10 mmol) in H.sub.2O (10 mL) was
added to
4-{[(4-tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]-amino}-2-(2--
chloro-benzylamino)-pyrimidine-5-carboxylic acid ethyl ester
dissolved in EtOH (15 mL) at room temperature. The mixture was
heated to 80.degree. C. for 6 h and then concentrated in vacuo
until a crude white precipitate formed. The crude product was
filtered, washed with EtOAc, and dried in vacuo to provide a white
powder 563 mg, 99%, m/z calculated for
C.sub.25H.sub.34ClN.sub.5O.sub.4: 504.0, found: 505.8
(M+H).sup.+.
[0123] To a solution of
4-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexyl-
methyl]-amino}-2-(2-chloro-benzylamino)-pyrimidine-5-carboxylic
acid (80 mg, 0.159 mmol) dissolved in 2:1 CHCl.sub.3:EtOH at room
temperature was added 4.0 M HCl/dioxane (5.0 mL). The mixture was
stirred at room temperature for 2 h then concentrated in vacuo to
provide a crude white powder. The crude material was purified by
preparative scale reverse phase HPLC using a 0.1%
TFA-H.sub.2O/CH.sub.3CN mobile phase. The product-containing
fractions were combined and concentrated in vacuo to provide 34 mg
of the title compound as a white solid, 53%, m/z calculated for
C.sub.20H.sub.26ClN.sub.5O.sub.2: 403.9, found: 404.4
(M+H).sup.+.
Example 7
[0124] Synthesis of
4-[(4-aminomethyl-cyclohexylmethyl)-amino]-2-(2-chloro-
-benzylamino)-pyrimidine-5-carboxylic acid methyl ester 195
[0125] To a solution of
4-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexyl-
methyl]-amino}-2-(2-chloro-benzylamino)-pyrimidine-5-carboxylic
acid (120 mg, .238 mmol) in 1:1 MeOH:CH.sub.2Cl.sub.2 (5 mL) was
added 2.0 M (trimethylsilyl)diazomethane in hexanes. The mixture
was stirred at room temperature for 18 h and then concentrated in
vacuo to provide a pale yellow solid which was purified by silica
gel chromatography using 0-60% EtOAc/hexanes. The
product-containing fractions were combined and concentrated in
vacuo to provide a white solid 80 mg, 65%, m/z calculated for
C.sub.26H.sub.36ClN.sub.5O.sub.4: 518.0, found: 519.7
(M+H).sup.+.
[0126] Treatment of the above tert-butoxycarbonyl protected amine
with 4.0 M HCl/dioxane as described for Example 1 provided the
title compound as a white powder 20 mg, 31%, m/z calculated for
C.sub.21H.sub.28ClN.sub.5O.su- b.2: 417.9, found:
418.4(M+H).sup.+.
Example 8
[0127] Synthesis of
4-[(4-aminomethyl-cyclohexylmethyl)-amino]-2-(2-chloro-
-benzylamino)-pyrimidine-5-carboxylic acid amide 196
[0128] DMF (7 mL) was added to
4-{[4-(tert-butoxycarbonylamino-methyl)-cyc-
lohexylmethyl]-amino}-2-(2-chloro-benzylamino)-pyrimidine-5-carboxylic
acid (120 mg, 0.238 mmol) (see Example 6),
1-[3-(dimethylamino)propyl]-3-- ethylcarbodiimide (50 mg, 0.262
mmol), and 1-hydroxybenzotriazole (35 mg, 0.262 mmol) at 0.degree.
C. After stirring for 0.5 h, ammonium hydroxide (0.170 mL, 1.190
mL) was added and the mixture was warmed to room temperature and
stirred for 18 h. The mixture was then concentrated in vacuo and
the residue dissolved in EtOAc (30 mL), and washed with 1 N HCl
(3.times.50 mL) followed by saturated NaHCO.sub.3 (3.times.50 mL).
The product solution was dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to provide a white solid. The crude product
was dissolved in 1:1 MeOH:CH.sub.2Cl.sub.2and purified by
preparative TLC using a 2% NH.sub.4OH, 18% MeOH, 80%
CH.sub.2Cl.sub.2 mobile phase. The product-containing band was
removed from the plate and washed with the mobile phase solution.
The mixture was filtered and the filtrate concentrated in vacuo to
provide a white solid 65 mg, 54%, m/z calculated for
C.sub.25H.sub.35ClN.sub.6O.sub.3: 503.0, found: 504.8
(M+H).sup.+.
[0129] Treatment of the above tert-butoxycarbonyl protected amine
with 4.0 M HCl/dioxane as described for Example 1 provided the
title compound as a white solid 31 mg, 60%, m/z calculated for
C.sub.20H.sub.27ClN.sub.60: 402.9, found: 403.4 (M+H).sup.+.
Example 9
[0130] Synthesis of
N-(4-{[2-(2-chloro-benzylamino)-5-nitro-pyrimidin-4-yl-
amino]-methyl}-cyclohexylmethyl)-guanidine 197
[0131] A mixture of
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-5-nitro-N.sup-
.2-(2-chloro-benzyl)-pyrmidine-2,4-diamine (110 mg, 270 mmol) and
1,3-bis(tert-butoxycarbonyl)-2-methyl thiopseudourea (95 mg, 330
mmol) in THF (5.0 mL) was stirred at room temperature for 3 days.
The reaction mixture was then concentrated and purified by silica
gel chromatography using a gradient of EtOAc in hexanes as the
eluant to provide 52 mg (30% yield) of the bis
(tert-butoxycarbonyl) protected guanidine a white solid, m/z
calculated for C.sub.30H.sub.43ClN8O.sub.6: 647.2, found: 648.8
(M+H).sup.+.
[0132] The above bis (tert-butoxycarbonyl) protected guanidine was
treated with 4N HCl/dioxane solution and stirred at room
temperature for 14 h. The reaction mixture was concentrated and the
resulting residue was purified by silica gel chromatography using a
gradient of ammonium hydroxide and MeOH in dichloromethane as the
eluant to provide 12 mg (37% yield) of the title compound as a
light yellow solid, m/z calculated for
C.sub.20H.sub.27ClN.sub.8O.sub.2: 446.0 found: 447.1
(M+H).sup.+.
Example 10
[0133] Synthesis of
N-(3-{[2-(2-chloro-benzylamino)-5-nitro-pyrimidin-4-yl-
amino]-methyl}-cyclohexylmethyl)-guanidine 198
[0134] This compound was prepared in an analogous fashion to
Example 9 using 1,3-cyclohexane bis (methylamine) as a starting
material in place of 1,4-cyclohexane bis (methylamine), m/z
calculated for C.sub.20H.sub.27ClN.sub.8O.sub.2: 446.0 found: 447.4
(M+H).sup.+.
Example 11
[0135] Synthesis of
N.sup.2-(2-chloro-benzyl)-5-nitro-N.sup.4piperidin-4-y-
lmethyl-pyrimidine2,4-diamine 199
[0136] This compound was prepared by the procedure described in
Example 1 using 2,5-dichloro-5-nitropyrimidine and
4-aminomethyl-1-N-Boc piperidine as starting materials. Subsequent
treatment of the tert-butoxycarbonyl intermediate with 4 N
HCl/dioxane provided the title compound, m/z calculated for
C.sub.17H.sub.21ClN.sub.6O.sub.2: 376.0 found: 377.5
(M+H).sup.+.
Example 12
[0137] Synthesis of
4-{[2-(2-chloro-benzylamino)-5-nitro-pyrimidin-4-ylami-
no]-methyl}-piperidine-1-carboxamidine 200
[0138] This compound was prepared in an analogous fashion to
Example 9 using
N.sup.2-(2-Chloro-benzyl)-5-nitro-N.sup.4piperidin-4-ylmethyl-pyrim-
idine2,4-diamine (Example 11) as a starting material in place of
N.sup.4-(4-Aminomethyl-cyclohexylmethyl)-5-nitro-N.sup.2-(2-chloro-benzyl-
)-pyrmidine-2,4-diamine, m/z calculated for
C.sub.18H.sub.23ClN.sub.8O.sub- .2: 418.0 found: 419.1
(M+H).sup.+.
Example 13
[0139] Synthesis of
3-({4-[(4-aminomethyl-cyclohexylmethyl)-amino]-5-nitro-
-pyrimidin-2-ylamino}-methyl)-N-(2-o-tolyl-ethyl)-benzamide 201
[0140] This compound was prepared in an analogous fashion to
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-5-nitro-N.sup.2-(2-chloro-benzyl-
)-pyrmidine-2,4-diamine using
3-aminomethyl-N-(2-o-tolyl-ethyl)-benzamide as a starting material
in place of 2-chloro benzylamine, m/z calculated for
C.sub.29H.sub.37N.sub.7O.sub.3: 531.0 found: 532.4 (M+H).sup.+.
[0141] 3-Aminomethyl-N-(2-o-tolyl-ethyl)-benzamide was prepared as
follows:
[0142] A solution of N-Boc-3-aminomethyl benzoic acid (1.00 g, 3.98
mmol), HOBT (600 mg, 4.44 mmol), and EDC (805 mg, 4.20 mmol) in DMF
(10 mL) was stirred at room temperature for 30 min. 2-Methyl
phenethylamine (575 uL, 4.08 mmol) was then added dropwise and the
reaction mixture was stirred overnight at room temperature. The
reaction mixture was concentrated and the resulting residue was
taken up in EtOAc (50 mL) and washed successively with NaHCO.sub.3
satd (2.times.50 mL) and 1N HCl (2.times.50 mL). The organic phase
was dried (MgSO.sub.4) and concentrated to provide 1.37 g (93%
yield) of the tert-butoxycarbonyl protected intermediate as a white
solid, m/z calculated for C.sub.22H.sub.28N.sub.2O.sub.3: 368.0
found: 369.4 (M+H).sup.+.
[0143] The above tert-butoxycarbonyl protected intermediate was
treated with 4N HCl/dioxane to provide the desired starting
material,
Example 14
[0144] Synthesis of
4-{4-[(4-aminomethyl-cyclohexylmethyl)-amino]-5-nitro--
pyrimidin-2-ylamino}-N-(2-o-tolyl-ethyl)-butyramide 202
[0145] This compound was prepared in an analogous fashion to
Example 13 using 4-tert-butoxycarbonyl aminobutyric acid as a
starting material in place of N-Boc-3-aminomethyl benzoic acid, m/z
calculated for C.sub.25H.sub.37N.sub.7O.sub.3: 483.0 found: 484.5
(M+H).sup.+.
Example 15
[0146] Synthesis of
5-{4-[(4-aminomethyl-cyclohexylmethyl)-amino]-5-nitro--
pyrimidin-2-ylamino}-pentanoic acid (2-o-tolyl-ethyl)-butyramide
203
[0147] This compound was prepared in an analogous fashion to
Example 13 using 5-tert-butoxycarbonyl aminovaleric acid as a
starting material in place of N-Boc-3-aminomethyl benzoic acid, m/z
calculated for C.sub.26H.sub.39N.sub.7O.sub.3: 497.0 found: 498.4
(M+H).sup.+.
Example 16
[0148] Synthesis of
6-{4-[(4-aminomethyl-cyclohexylmethyl)-amino]-5-nitro--
pyrimidin-2-ylamino}-hexanoic acid (2-o-tolyl-ethyl)-butyramide
204
[0149] This compound was prepared in an analogous fashion to
Example 13 using 6-tert-butoxycarbonylamino hexanoic acid as a
starting material in place of N-Boc-3-aminomethyl benzoic acid, m/z
calculated for C.sub.27H.sub.41N.sub.7O.sub.3: 511.0 found: 512.5
(M+H).sup.+.
Example 17
[0150] Synthesis of
N.sup.4-{[4-(aminomethyl)cyclohexl]methyl}-N.sup.2-(2--
bromobenzyl)-5-nitropyrimidine-2,4-diamine 205
[0151] 2-Chloro-5-nitro-4-thiocyanatopyrimidine (100 mg, 0.46 mmol)
was suspended in 1 mL absolute EtOH. o-Bromobenzylamine
hydrochloride (103 mg, 0.46 mmol) was dissolved in 1 mL absolute
EtOH and added to the reaction quickly at ambient temperature. Then
triethylamine (129 .mu.L, 0.92 mmol) was added dropwise via
syringe. The reaction was stirred 16 h at ambient temperature. The
resulting precipitate was filtered providing 136 mg of the desired
(2-bromo-benzyl)-(5-nitro-4-thiocyanato-pyrimidin-2- -yl)-amine as
a white solid.
[0152] 1,4-Cyclohexanebis(methylamine) (65 mg, 0.46 mmol) was
dissolved in 1 mL dichloromethane and added to a suspension of
(2-bromo-benzyl)-(5-nit- ro-4-thiocyanato-pyrimidin-2-yl)-amine (40
mg, 0.11 mmol) in 1 mL dichloromethane. The reaction was shaken 16
h at ambient temperature. The reaction mixture was then loaded
directly onto a 4.5 g pre-packed disposable flash cartridge and
eluted with a gradient (solvent system: A=dichloromethane and B=10%
ammonium hydroxide in MeOH). The title compound (43 mg, 89%) was
isolated as a yellow solid.
Example 18
[0153] Synthesis of
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-5-nitro-N.sup-
.2-(1-phenyl-cyclopropyl)-pyrimidin-2,4-diamine 206
[0154] To a solution of 1.0 g (6.2 mmol)of 1-phenyl-1-cyclopropane
carboxylic acid in CH.sub.2Cl.sub.2 (30 mL) at room temperature was
added 2.0 mL (9.0 mmol) of diphenylphosphoryl azide (DPPA) and 1.3
mL (9.3 mmol) of triethylamine. The reaction mixture was stirred at
room temperature for 3 h then poured into ice water and acidified
to pH 2 with 6N HCl. The phases were separated and the aqueous
phase washed with CH.sub.2Cl.sub.2. The combined organics were
washed with H.sub.2O followed by brine then dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure. The
residue was taken up in EtOH (30 mL) and heated at reflux for 8 h.
The reaction was cooled to room temperature and concentrated under
reduced pressure. The residue was diluted with EtOAc and washed
with H.sub.2O followed by brine then dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide
a white oil. The product was purified by flash silica gel
chromatography using a 0-10% graident of EtOAc:hexanes to provide
(1-phenyl-cyclopropyl)-carbamic acid ethyl ester 0.85 g (69%) as a
white solid. m/z cacld. C.sub.9H.sub.12N [M-ethylcarbamate+H].sup.+
134.20. Found: 133.90.
[0155] To a suspension of 0.84 g (4.1 mmol) of the above carbamate
in a 1:2 mixture of H.sub.2O:ethylene glycol (4.5 mL) was added 1.0
g (25 mmol) of sodium hydroxide as a solid in one portion. The
slurry was heated to 110.degree. C. for 15 h during which time a
solid precipitated out of solution. The mixture was cooled to room
temperature and poured into a solution of 2N HCl (30 mL). The
mixture was washed with Et.sub.2O and the aqueous layer made basic
to pH 12 by addition of 6N NaOH. The aqueous phase was washed with
CH.sub.2Cl.sub.2 and the combined organic phase was dried over
anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure
to provide 0.046 g (8%) of 1-phenyl-cyclopropylamine as a clear
oil. m/z cacld. C.sub.9H.sub.12N [M+H].sup.+: 134.20. Found:
133.90.
[0156]
(5-Nitro-4-thiocyanato-pyrimidin-2-yl)-(1-phenyl-cyclopropyl)-amine
was prepared by addition of the above amine to
2-chloro-5-nitro-4-thiocya- nato-pyrimidine using the procedure
described in Example 17. m/z calcd. C.sub.14H.sub.10N.sub.5O.sub.2S
[M-H].sup.-: 312.33. Found: 312.10.
[0157] The title compound was prepared from the above intermediate
by addition of 1,4-cyclohexanebis(methylamine) using the procedure
described in Example 17. m/z calcd. C.sub.21H.sub.29N.sub.6O.sub.2
[M+H].sup.+: 397.50. Found: 397.04.
Example 19
[0158] Synthesis of
N.sup.4-(4-aminomethyl-cyclohexylmethyl)-N.sup.2-[1-(2-
-chloro-phenyl)-1-methyl-ethyl]-5-nitro-pyrimidine-2,4-diamine
207
[0159] To a solution of 10.0 g (59 mmol) (2-chlorophenyl) acetic
acid in MeOH (10 mL) was added 9.6 mL (88 mmol) of trimethyl
orthoformate and 0.32 mL (6.0 mmol) of H.sub.2SO.sub.4. The
reaction was stirred at room temperature for 4 h then diluted with
EtOAc and washed with H.sub.2O followed by a saturated aqueous
solution of NaHCO.sub.3. The organic phase was dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide
10.6 g (97%) of (2-chlorophenyl)-acetic acid methyl ester as a
clear oil. The crude reaction product was not purified but used
immediately.
[0160] To a mixture of 2.0 g (11 mmol) of the above ester and 1.4
mL (11 mmol) of iodo methane in THF (50 mL) cooled to 0.degree. C.
was added dropwise a solution of sodium bis(trimethylsilyl)amide
(22 mL of a 1.0 M solution in THF). The reaction was allowed to
slowly warm up to room temperature and stirred for 14 h. The
reaction was cooled to 0.degree. C. and an additional 1.4 mL (11
mmol) of iodo methane was added. To this mixture was added dropwise
a solution of sodium bis(trimethylsilyl)amide (22 mL of a 1.0 M
solution in THF). The reaction was allowed to slowly warm to room
temperature and stirred for 8 h. The mixture was cooled to
0.degree. C. and the reaction was quenched by addition of a
saturated aqueous solution of NH.sub.4Cl. The mixture was diluted
with H.sub.2O and extracted with EtOAc. The combined organic phase
was washed with brine, dried over anhydrous Na.sub.2SO.sub.4, and
concentrated under reduced pressure to provide 2.2 g (95%) of
2-(2-chlorophenyl)-2-methyl-propionic acid methyl ester as a brown
oil.
[0161] To a solution of 2.2 g (10 mmol) of the above ester in MeOH
(60 mL) was added an aqueous solution of KOH (60 mL of a 1.0 M
solution). The reaction mixture was heated to reflux for 15 h. The
mixture was cooled to room temperature and washed with Et.sub.2O
then acidified to pH 2 with a solution of 2N HCl. The aqueous layer
was extracted with CH.sub.2Cl.sub.2, dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure to provide
0.55 g (27%) of 2-(2-chlorophenyl)-2-me- thyl-propionic acid as a
light brown solid. The crude reaction product was not purified but
used immediately.
[0162] To a solution of 0.55 g (2.8 mmol) of the above acid in
CH.sub.2Cl.sub.2 (15 mL) at room temperature was added 0.90 mL (4.2
mmol) of DPPA and 0.58 mL (4.1 mmol) of triethyl amine. The
reaction mixture was stirred at room temperature for 3 h then
poured into ice water and acidified to pH 2 with 6N HCl. The phases
were separated and the aqueous phase washed with CH.sub.2Cl.sub.2.
The combined organics were washed with H.sub.2O followed by brine
then dried over anhydrous Na.sub.2SO.sub.4 and concentrated under
reduced pressure. The residue was taken up in EtOH (15 mL) and
heated at reflux for 15 h. The reaction was cooled to room
temperature and concentrated under reduced pressure. The crude
residue was purified by flash silica gel chromatography using a
0-10% gradient of EtOAc: hexanes to provide 0.31 g (46%) of
[1-(2-chlorophenyl)-1-methyl -ethyl]-carbamic acid ethyl ester a
clear oil. m/z calcd. C.sub.12H.sub.17ClNO.sub.2 [M+H].sup.+:
242.73. Found:241.97.
[0163] To a suspension of 0.31 g (1.3 mmol) in a 1:2 mixture of
H.sub.2O:ethylene glycol (4.5 mL) was added 0.30 g (7.5 mmol) of
sodium hydroxide as a solid in one portion. The slurry was heated
to 110.degree. C. for 15 h during which time a solid precipitated
out of solution. The reaction was cooled to room temperature and
poured into a solution of 2N HCl (30 mL) the reaction was washed
with Et.sub.2O and the aqueous layer made basic to pH 12 by
addition of 6N NaOH. The aqueous phase was washed with
CH.sub.2Cl.sub.2 and the combined organic phase was dried over
anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure
to provide 0.078 g (36%) of 1-(2-chlorophenyl)-1-methyl-ethlamine a
clear oil. m/z calcd. C.sub.9H.sub.13ClN [M+H].sup.+: 170.66.
Found: 169.91.
[0164]
[1-(2-Chlorophenyl)-1-methyl-ethyl]-(5-nitro-4-thiocyanato-pyrimidi-
n-2-yl)-amine was prepared by addition of the above amine to
2-chloro-5-nitro-4-thiocyanato-pyrimidine using the procedure
described in Example 17. m/z calcd.
C.sub.14H.sub.11N.sub.5O.sub.2S[M-H].sup.-: 348.79. Found:
348.05
[0165] The title compound was prepared from the above intermediate
by addition of 1,4-cyclohexanebis(methylamine) using the procedure
described in Example 17. m/z calcd.
C.sub.21H.sub.30ClN.sub.6O.sub.2 [M+H].sup.+: 433.97. Found:
433.04.
Example 20
[0166] Synthesis of
N.sup.4-(4-dimethylaminomethyl-cyclohexylmethyl)-N.sup-
.2-(2-methylsulfanyl-benzyl)-5-nitro-pyrimidine-2,4-diamine 208
[0167] To a solution of 0.035 g (0.08 mmol) of
N.sup.4-(4-aminomethyl-cycl-
ohexylmethyl)-N.sup.2-(2-methylsulfanyl-benzyl)-5-nitro-pyrimidine-2,4-dia-
mine (prepared by the procedure described in Example 17, using
2-methylsulfanyl-benzylamine) in MeOH (1 mL) containing 1% v/v AcOH
and cooled to 0.degree. C. was added 0.03 mL (0.4 mmol) of a 37%
aqueous formaldehyde solution. To this mixture was added 0.010 g
(0.16 mmol) of sodium cyanoborohydride as a solid in one portion.
The reaction mixture was allowed to slowly warm to room temperature
and stirred for 2 h. The reaction was diluted with a saturated
aqueous solution of NaHCO.sub.3 and washed with CH.sub.2Cl.sub.2.
The combined organic phase was dried over anhydrous
Na.sub.2SO.sub.4 and concentrated under reduced pressure. The
residue was purified by flash silica gel chromatography using a
0-40% gradient of A (18% MeOH, 2% NH.sub.4OH, 80% CH.sub.2Cl.sub.2)
to B (CH.sub.2Cl.sub.2) to provide 0.0083 g (22%) of a white
powder. m/z calcd. C.sub.22H.sub.32N.sub.6O.sub.2S [M+H].sup.+:
445.6. Found: 445.5.
[0168] The other specific compounds listed in the Table set forth
previously were prepared by methods analogous to those set forth in
the General Synthetic Methods section and the Synthetic Examples
above.
Assessment of Biological Activity
[0169] PKC-theta Inhibition Assay
[0170] The ability of compounds to inhibit the kinase activity of
PKC-theta was measured using a competitive Fluorescent Polarization
Assay (PanVera R2748). Human recombinant PKC-theta (PanVera R2996),
was used at a final concentration of 50 nM in a kinase assay buffer
(20 mM HEPES, pH 7.6, 10 mM MgCl.sub.2, 0.1 mM CaCl.sub.2, 0.01%
CHAPS, 100 microM Ortho V anadate (Sigma), Protease Inhibitor
Cocktail (Roche), 200 microM TCEP). PKC-theta was incubated with
test compound for 10 minutes at room temperature. PKC-alpha
pseudosubstrate (RFARKGSLRQKNV; PanVera R2760) at a final
concentration of 1 microM and ATP (Amersham 27-2056-01) at a final
concentration of 10 microM were added and incubated 60 minutes at
room temperature. The kinase reaction was stopped by adding an
anti-phosphoserine containing peptide antibody and
fluorescein-labeled phosphopeptide tracer ("F-phosphopeptide")
diluted in a quench buffer containing EDTA. The FP reaction was
incubated for 90 minutes at room temperature. Phosphopeptide,
generated by the kinase activity of PKC-theta, competes with the
F-phosphopeptide for the anti-phosphopeptide antibody. Inhibition
of kinase activity will result in the binding of the antibody to
the F-phosphopeptide, yielding an increase in the fluorescence
polarization. Change in polarization was measured on an LJL
Criterion Analyst with 485 nm excitation filter, 530 mn emission
filter, and 505 nm dichroic mirror.
[0171] All compounds in the synthetic examples and Tables above
were evaluated in the PKC-theta assay above and were found to have
IC.sub.50's less than 10 microM. Preferred compounds had
IC.sub.50's equal to or less than 0.3 microM.
[0172] Many of the compounds in the synthetic examples and Tables
above were also tested against Syk, Lyn, Veg-f and insulin receptor
kinase to evaluate selectivity for PKC-theta inhibition. Some
compounds were also tested against other kinases including CDK-5,
CDK-1 and PLK. Many of the compounds demonstrated selectivity for
the inhibition of PKC-theta as compared to one or more of the other
kinases tested.
[0173] Assay conditions for testing against other kinases are
generally known in the art. Examples of suitable assays that can be
used are described below:
[0174] SYK Kinase Assay
[0175] SYK is purified as a GST-fusion protein. The kinase activity
is measured using DELFIA (Dissociation Enhanced Lanthanide
Fluoroimmunoassay) which utilizes europium chelate-labeled
anti-phosphotyrosine antibodies to detect phosphate transfer to a
random polymer, poly Glu.sub.4: Tyr.sub.1 (PGTYR).
[0176] The kinase assay is performed in kinase assay buffer (50 mM
HEPES, pH 7.0, 25 mM MgCl.sub.2, 5 mM MnCl.sub.2, 50 mM KCl, 100
.mu.M Na.sub.3VO.sub.4, 0.2% BSA, 0.01% CHAPS). Test samples
initially dissolved in DMSO at 1 mg/mL, may be pre-diluted for dose
response (11 doses with starting final concentration of 30
.mu.g/mL, 1 to 3.5 serial dilutions) with the assay buffer in
96-well polypropylene microtiter plates. A 25 .mu.L aliquot of this
diluted sample is added to neutravidin coated 96-well white plate
(PIERCE). A 25 .mu.L volume of diluted enzyme (0.6 ng/mL final
conc.) and a 50 .mu.L volume of a mixture of substrates containing
200 nM ATP and 3.6 ng/.mu.L PGTYR-biotin (CIS Biointemational) in
kinase buffer is sequentially added to the assay plates. Background
wells are incubated with buffer, rather than 25 .mu.L enzyme. The
assay plates are incubated for 30 minutes at room temperature.
Following incubation, the assay plates are washed three times with
300 .mu.L wash buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 0.05%
Tween 20, 0.2% BSA). A 100 .mu.L aliquot of europium-labeled
anti-phosphotyrosine (Eu.sup.3+-PT66, Wallac CR.sub.04-100) diluted
in 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 10 .mu.M DTPA, 0.05% Tween
40, 0.2% BSA, 0.05% BGG (1 nM final conc.) is added to each well
and incubated for 30 minutes at room temperature. Upon completion
of the incubation, the plate is washed four times with 300 .mu.L of
wash buffer and 100 .mu.L of DELFIA Enhancement Solution (Wallac)
is added to each well. After 10 minutes or longer, time-resolved
fluorescence is measured on the LJL's Analyst (excitation at 360
nm, emission at 620 nm, EU 400 Dichroic Mirror) after a delay time
of 250 .mu.s.
[0177] CDK Kinase Assay
[0178] 1. Preparation of Recombinant Cyclin-CDK Enzymes
[0179] The corresponding cDNAs for human cyclin B1 (cyclin E, or.
cyclin D1) and human CDK1 (CDK2, or. CDK4) are cloned by standard
methods using RT-PCR, and cloned into a transfer vector (cyclin in
pAcG2T made by Pharmingen, CDKs in p2Bac made by Invitrogen) for
the baculovirus system. Recombinant cyclin B1-CDK1 (or cyclin
E-CDK2, cyclin D1-CDK4) is expressed in High Five insect cells
(Trichoplusia ni) by coinfection with both recombinant
baculoviruses (after the 4th round of amplification,
>1.times.10.sup.8 viruses/ml). 72 h after the infection the High
Five cells are harvested, and deep-frozen in liquid nitrogen. After
thawing the cells are resuspended in lysing buffer (50 mM HEPES pH
7.5, 10 mM MgCl.sub.2, 1 mM DTT, 5 .mu.g/ml leupeptin, 5 .mu.g/ml
aprotinin, 100 .mu.M NaF, 100 .mu.M PMSF, 10 mM
.beta.-glycerolphosphate, 100 .mu.M Na.sub.3VO.sub.4, 30 mM
nitrophenylphosphate, 17.5 ml of lysing buffer per 10.sup.8 cells)
and incubated on ice for 30 min. The cell lysate is freed from the
cell debris by centrifugation and the quantity of recombinant
cyclin B1-CDK1 enzyme (or cyclin E-CDK2, cyclin D1-CDK4) in the
total lysate (about 1-5 mg/ml) is determined by SDS-polyacrylamide
gel electrophoresis. Cyclin D1-CDK4 is purified by means of a
GST-tag on cyclin D1 and then using glutathione beads (total
protein about 0.2 mg/ml).
[0180] 2. Cyclin B1-CDK1 Kinase Inhibition Test
[0181] All the kinase tests may be carried out in 96-well
microtitre plates (Greiner PS) in a final volume of 60 .mu.l. The
kinase test contain 1% DMSO (v/v), 5 .mu.g of histone H1 (calf
thymus, Roche Molecular Biochemicals), 1 to 5 .mu.g of a cell
lysate with recombinant cyclin B1/CDK1, the test substance (in a
final concentration of 1 nM to 10 .mu.M) and kinase buffer (15 mM
MgCl2, 25 mM MOPS, pH 7.0, 0.1 mM DTT). As a negative control the
kinase reaction is carried out in the absence of the substrate
histone H1. As a positive control the kinase reaction is carried
out in the absence of a test substance. As an internal control 30
.mu.M and 300 .mu.M (final concentration) of the kinase inhibitor
olomoucin (Alexis) are used.
[0182] The PS microtitre plates are placed on ice, and 10 .mu.l of
the test substance, in different concentrations (in each case in 6%
DMSO), 20 .mu.l of the histone H1 (250 .mu.g/ml in kinase buffer)
and 20 .mu.l of cyclin B1/CDK1 (1 to 5 .mu.g of the recombinant
cell lysate in 20 .mu.l of kinase buffer) are pipetted in and mixed
together. The kinase reaction is started by the addition of 10
.mu.l of ATP mix (0.045 mM ATP, 0.5 .mu.Ci [.gamma.-.sup.33P]ATP in
kinase buffer) and incubated for 30 min at 30.degree. C. and 600
rpm in a shaking incubator. After incubation the plates are placed
on ice and the proteins are precipitated by the addition of 125
.mu.l of ice-cold 5% trichloroacetic acid. After 15 min on ice the
precipitates are transferred onto Packard Unifilter 96 GF/B plates
with the Packard Harvester System, and collected by vacuum
filtration. The precipitates are washed 4 times with dist. H.sub.2O
at ambient temperature. The filter plates are then dried at
60.degree. C. and 50 .mu.l of scintillation liquid are added to
each well (Ultima Gold, Packard). The plate is sealed up with
Sealing Tape and after 1 h measured in a scintillation measuring
apparatus (Micro Beta made by Wallac).
[0183] The inhibition of the substances is calculated as a
percentage of the control (cyclin B1-CDK1 without inhibitor) and
the active substance concentration which inhibits the enzyme
activity by 50% (IC50) is derived.
[0184] 3. Cyclin E-CDK2 Kinase Inhibition Test
[0185] The inhibition test with cyclin E-CDK2 is carried out using
the same method as for cyclin B1-CDK1, except that recombinant
cyclin E-CDK2 is used as the enzyme.
[0186] 4. Cyclin D1-CDK4 Kinase Inhibition Test
[0187] For the inhibition test with cyclin D1-CDK4, recombinant
Retinoblastoma Protein (pRB) from aa379-928, which contains a
GST-tag at the N-terminus, is used as the substrate. GST-pRB is
expressed in bacteria and then purified using glutathione beads (
about 0.2 mg/ml). The kinase test contains 1% DMSO (v/v), 10 .mu.g
pRB, 0.4 .mu.g of a cell lysate with recombinant cyclin D1-CDK4,
the test substance (final concentration from 1 nM to 10 .mu.M) and
kinase buffer (15 mM MgCl.sub.2, 25 mM MOPS, pH 7.0, 0.1 mM DTT).
As a negative control the kinase reaction is carried out in the
absence of the substrate pRB. As a positive control the kinase
reaction is carried out in the absence of a test substance. As an
internal control 30 .mu.M and 300 .mu.M (final concentration) of
the kinase inhibitor olomoucin (Alexis) are used.
[0188] The PS microtitre plates are placed on ice, and 10 .mu.l of
the test substance, in different concentrations (in each case in 6%
DMSO), 20 .mu.l of pRB (10 .mu.g in kinase buffer) and 20 .mu.l of
cyclin D1-CDK4 (0.4 .mu.g of the recombinant cell lysate in 20
.mu.l of kinase buffer) are pipetted in and mixed together. The
kinase reaction is started by the addition of 10 .mu.l of ATP mix
(0.045 mM ATP, 1 .mu.Ci [.gamma.-.sup.33P]ATP in kinase buffer) and
incubated for 45 min at 32.degree. C. and 600 rpm in a vibrating
incubator. After incubation, 50 .mu.l of the reaction mixture are
pipetted onto P81 filters (Whatmann). After 20 sec reaction time
the filters are washed 4 times with 1.5% phosphoric acid (about 5
min per washing step) while shaking them gently. After washing the
filters are dried at 85.degree. C., scintillation liquid is added
and the scintillation is measured in a scintillation counter (Micro
Beta made by Wallac).
Methods of Therapeutic Use
[0189] The compounds of the invention are effective inhibitors of
PKC-theta activity, and therefore are useful to inhibit PKC-theta
activity in a patient and treat a variety of diseases and disorders
that are mediated or sustained through the activity of
PKC-theta.
[0190] Without wishing to be bound by theory, the compounds of this
invention would be expected to inhibit T cell activation via
effective inhibition of PKC-theta, and are therefore useful to
treat diseases and disorders associated with T cell activation. For
example, the inhibition of T cell activation is therapeutically
useful for selectively suppressing the immune function. Thus, the
inhibition of PKC-theta with the compounds of this invention is an
attractive means for treating a variety of immunological disorders,
including inflammatory diseases, autoimmune diseases, organ and
bone marrow transplant rejection and other disorders associated
with T cell mediated immune response. In particular, the compounds
of the invention may be used to treat acute or chronic
inflammation, allergies, contact dermatitis, psoriasis, rheumatoid
arthritis, multiple sclerosis, type I diabetes, inflammatory bowel
disease, Guillain-Barre syndrome, Crohn's disease, ulcerative
colitis, graft versus host disease (and other forms of organ or
bone marrow transplant rejection) and lupus erythematosus. Other
disorders associated with T cell-mediated immune responses will be
evident to those of ordinary skill in the art and can also be
treated with the compounds and compositions of this invention.
[0191] In addition, PKC theta activation has been shown to be
associated with insulin resistance in skeletal muscle. Therefore,
the inhibition of PKC-theta with the compounds of this invention is
also an attractive means for treating type II diabetes.
[0192] For therapeutic use, the compounds of the invention may be
administered via a pharmaceutical composition in any conventional
pharmaceutical dosage form in any conventional manner. Conventional
dosage forms typically include a pharmaceutically acceptable
carrier suitable to the particular dosage form selected. Routes of
administration include, but are not limited to, intravenously,
intramuscularly, subcutaneously, intrasynovially, by infusion,
sublingually, transdermally, orally, topically or by inhalation.
The preferred modes of administration are oral and intravenous.
[0193] The compounds of this invention may be administered alone or
in combination with adjuvants that enhance stability of the
inhibitors, facilitate administration of pharmaceutical
compositions containing them in certain embodiments, provide
increased dissolution or dispersion, increase inhibitory activity,
provide adjunct therapy, and the like, including other active
ingredients. In one embodiment, for example, multiple compounds of
the present invention can be administered. Advantageously, such
combination therapies utilize lower dosages of the conventional
therapeutics, thus avoiding possible toxicity and adverse side
effects incurred when those agents are used as monotherapies.
Compounds of the invention may be physically combined with the
conventional therapeutics or other adjuvants into a single
pharmaceutical composition. Advantageously, the compounds may then
be administered together in a single dosage form. In some
embodiments, the pharmaceutical compositions comprising such
combinations of compounds contain at least about 5%, but more
preferably at least about 20%, of a compound of formula (I) (w/w)
or a combination thereof. The optimum percentage (w/w) of a
compound of the invention may vary and is within the purview of
those skilled in the art. Alternatively, the compounds of the
present invention and the conventional therapeutics or other
adjuvants may be administered separately (either serially or in
parallel). Separate dosing allows for greater flexibility in the
dosing regime.
[0194] As mentioned above, dosage forms of the compounds of this
invention may include pharmaceutically acceptable carriers and
adjuvants known to those of ordinary skill in the art and suitable
to the dosage form. These carriers and adjuvants include, for
example, ion exchangers, alumina, aluminum stearate, lecithin,
serum proteins, buffer substances, water, salts or electrolytes and
cellulose-based substances. Preferred dosage forms include tablet,
capsule, caplet, liquid, solution, suspension, emulsion, lozenges,
syrup, reconstitutable powder, granule, suppository and transdermal
patch. Methods for preparing such dosage forms are known (see, for
example, H. C. Ansel and N. G. Popovish, Pharmaceutical Dosage
Forms and Drug Delivery Systems, 5th ed., Lea and Febiger (1990)).
Dosage levels and requirements for the compounds of the present
invention may be selected by those of ordinary skill in the art
from available methods and techniques suitable for a particular
patient. In some embodiments, dosage levels range from about 1-1000
mg/dose for a 70 kg patient. Although one dose per day may be
sufficient, up to 5 doses per day may be given. For oral doses, up
to 2000 mg/day may be required. As the skilled artisan will
appreciate, lower or higher doses may be required depending on
particular factors. For instance, specific dosage and treatment
regimens will depend on factors such as the patient's general
health profile, the severity and course of the patient's disorder
or disposition thereto, and the judgment of the treating
physician.
* * * * *